[
{"protocolSection":{"identificationModule":{"nctId":"NCT05039866","orgStudyIdInfo":{"id":"ST-920-LT01"},"organization":{"fullName":"Sangamo Therapeutics","class":"INDUSTRY"},"briefTitle":"Long-Term Follow-up of Subjects Who Were Treated with ST-920","officialTitle":"Long-Term Follow-up of Fabry Disease Subjects Who Were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase a Gene Therapy"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"ENROLLING_BY_INVITATION","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-08-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2029-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2039-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-08-20","studyFirstSubmitQcDate":"2021-09-01","studyFirstPostDateStruct":{"date":"2021-09-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-27","lastUpdatePostDateStruct":{"date":"2025-01-29","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sangamo Therapeutics","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.","detailedDescription":"Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion."},"conditionsModule":{"conditions":["Fabry Disease","Fabry Disease, Cardiac Variant"],"keywords":["Fabry Disease","Gene Therapy","ST-920","Rare","Genetic","DNA","Sangamo","Long Term"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"PROSPECTIVE"},"bioSpec":{"retention":"SAMPLES_WITH_DNA","description":"plasma, serum"},"enrollmentInfo":{"count":48,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Subjects who received ST-920","description":"Subjects who received ST-920 in a separate parent trial","interventionNames":["Biological: ST-920"]}],"interventions":[{"type":"BIOLOGICAL","name":"ST-920","description":"No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.","armGroupLabels":["Subjects who received ST-920"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To evaluate long-term safety of ST-920","description":"To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)","timeFrame":"4 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who received ST-920 therapy in a separate parent trial\n* Subjects who have consented to participate in this LTFU study.\n\nExclusion Criteria:\n\n-This study has no exclusion criteria","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"All subjects who have received ST-920 in separate parent trial and who have consented to participate in this Long Term Follow-up study.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Sangamo Therapeutics, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of California, Irvine","city":"Irvine","state":"California","zip":"92697","country":"United States","geoPoint":{"lat":33.66946,"lon":-117.82311}},{"facility":"University of South Florida","city":"Tampa","state":"Florida","zip":"33620","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Emory University School of Medicine","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"University of Iowa Hospital and Clinics","city":"Iowa City","state":"Iowa","zip":"52242","country":"United States","geoPoint":{"lat":41.66113,"lon":-91.53017}},{"facility":"University of Minnesota Medical Center","city":"Minneapolis","state":"Minnesota","zip":"55455","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Mt. Sinai Hospital","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Cincinnati Children's Hospital Medical Center","city":"Cincinnati","state":"Ohio","zip":"45229","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}},{"facility":"Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)","city":"Fairfax","state":"Virginia","zip":"22030","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"The Royal Melbourne Hospital","city":"Parkville","state":"Victoria","zip":"3050","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"M.A.G.I.C. Clinic Ltd.","city":"Calgary","state":"Alberta","zip":"T2E 7Z4","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Addenbrooke's Hospital","city":"Cambridge","zip":"CB2 0QQ","country":"United Kingdom","geoPoint":{"lat":52.2,"lon":0.11667}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D000795","term":"Fabry Disease"}],"ancestors":[{"id":"D013106","term":"Sphingolipidoses"},{"id":"D020140","term":"Lysosomal Storage Diseases, Nervous System"},{"id":"D020739","term":"Brain Diseases, Metabolic, Inborn"},{"id":"D001928","term":"Brain Diseases, Metabolic"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D059345","term":"Cerebral Small Vessel Diseases"},{"id":"D002561","term":"Cerebrovascular Disorders"},{"id":"D014652","term":"Vascular Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"},{"id":"D040181","term":"Genetic Diseases, X-Linked"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D008661","term":"Metabolism, Inborn Errors"},{"id":"D008064","term":"Lipidoses"},{"id":"D008052","term":"Lipid Metabolism, Inborn Errors"},{"id":"D016464","term":"Lysosomal Storage Diseases"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D052439","term":"Lipid Metabolism Disorders"}],"browseLeaves":[{"id":"M4124","name":"Fabry Disease","asFound":"Fabry Disease","relevance":"HIGH"},{"id":"M15904","name":"Sphingolipidoses","relevance":"LOW"},{"id":"M18871","name":"Lysosomal Storage Diseases","relevance":"LOW"},{"id":"M5204","name":"Brain Diseases","relevance":"LOW"},{"id":"M5205","name":"Brain Diseases, Metabolic","relevance":"LOW"},{"id":"M22498","name":"Brain Diseases, Metabolic, Inborn","relevance":"LOW"},{"id":"M5742","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M29437","name":"Cerebral Small Vessel Diseases","relevance":"LOW"},{"id":"M5810","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M17400","name":"Vascular Diseases","relevance":"LOW"},{"id":"M24877","name":"Genetic Diseases, X-Linked","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"M11641","name":"Metabolism, Inborn Errors","relevance":"LOW"},{"id":"M11064","name":"Lipidoses","relevance":"LOW"},{"id":"M11054","name":"Lipid Metabolism, Inborn Errors","relevance":"LOW"},{"id":"M11639","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M27029","name":"Lipid Metabolism Disorders","relevance":"LOW"},{"id":"T2169","name":"Fabry Disease","asFound":"Fabry Disease","relevance":"HIGH"},{"id":"T5335","name":"Sphingolipidosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT03128268","orgStudyIdInfo":{"id":"16-845-LHH"},"organization":{"fullName":"Northwell Health","class":"OTHER"},"briefTitle":"The Effectiveness of 4D Image Acquisition and Post-processing With Vios Works","officialTitle":"THE EFFECTIVENESS OF 4D IMAGE ACQUISITION AND POST-PROCESSING WITH VIOS WORKS: A Phase Design Prospective Clinical Trial to Assess 4D Software Produced by GE and Arterys for Evaluating Cardiac Disease."},"statusModule":{"statusVerifiedDate":"2022-10","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-02-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-04-26","type":"ACTUAL"},"completionDateStruct":{"date":"2023-06-20","type":"ESTIMATED"},"studyFirstSubmitDate":"2017-04-03","studyFirstSubmitQcDate":"2017-04-19","studyFirstPostDateStruct":{"date":"2017-04-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-10-25","lastUpdatePostDateStruct":{"date":"2022-10-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Michael Poon","investigatorTitle":"Chief, Non-invasive Cardiac Imaging","investigatorAffiliation":"Northwell Health"},"leadSponsor":{"name":"Northwell Health","class":"OTHER"},"collaborators":[{"name":"GE Healthcare","class":"INDUSTRY"},{"name":"Arterys, Inc.","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUnapprovedDevice":true,"isUsExport":false},"descriptionModule":{"briefSummary":"This study aims to evaluate the effectiveness of 4D image acquisition and post-processing with Vios Works for the evaluation of 3D images acquired on GE Magnetic Resonance Imaging scanners. Specifically, the investigators propose to evaluate the following:\n\n1. Image acquisition time using traditional 2D and new 4D processing techniques;\n2. Image quality for 2D and 4D processing techniques subjectively\n3. Post-processing time for the two techniques.\n4. Correlation of overall Left ventricular and right ventricular volumes and functions and aortic and pulmonic flow studies using the two techniques.\n5. The study will monitor any changes in patient diagnoses or treatment resulting from any differences in interpretations between the two processes.","detailedDescription":"Traditional scanning and post-processing of 2D Cardiac Magnetic Resonance images (CMRI) is highly technical and time consuming, with many exams requiring one to two hours to complete. In addition, performance of 2D scans often requires expert technologists working closely with the clinician imaging expert. These factors limit the general clinical utility of current generation cardiac MRI.\n\nIn order to address these factors, many researchers began to explore the use of 4D image acquisition and post processing to shorten exam time. These researchers have documented success at these efforts but, to the best of the current investigators' knowledge, such advanced imaging acquisition and post-processing systems are not readily commercially available in the US.\n\nRecently GE teamed with Vios-Works for MRI to provide a cloud-based visualization platform for 4D MRI that provides quantitative and structured reporting in the post processing environment that makes use of advance MR imaging acquisition techniques. The images can be accessed by the interpreter and reviewed and manipulated in order to assess cardiac function and flow retrospectively, which, prior to this innovation, only has been available for computed tomography (CT) generated images.\n\nThis investigative team hypothesizes that the use of 4D imaging will result in reduced time for acquisition (approximately 6 minutes as opposed to 1 hour), and improvement of diagnostic capability.\n\nImages will be acquired using the current standard 2D acquisition protocol for routine clinical cardiac MRI. A repeat acquisition will be completed using the new protocol for 4D imaging acquisition. This will require that patient exams be extended in length by six minutes for those enrolled in the study. The investigators will evaluate the image quality of the two techniques and grade them according to a scale of 1 to 3 with 1 being excellent cardiac borders easily identified; 2 - acceptable: cardiac borders acceptably identified; and 3, non-diagnostic. The investigators will specifically focus on the evaluation of cardiac function of both right and left ventricular function as well as flow analysis of both the aortic and pulmonic valves.\n\nFor each method, technician time and MD time will be collected. The exam will go through post processing for standard 2D, following by the new 4D post processing technique. Time for post processing will be collected. All subjects who agree will receive both a 2D and a 4D MRI. The investigators will evaluate inter and intra reader reliability by having all readers read the first 15 exams, and then read them a second time after two weeks in a different order Readers showing variation in performance will be retrained on interpretation of 4D MRI before reading scans for the study.\n\nOnce readers have been trained, the study will require that all 2D and 4D exams be read by two readers. The exams will be assigned randomly to readers using the Biostatistician Office random assignment services."},"conditionsModule":{"conditions":["Cardiac Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","interventionModelDescription":"Each participant will receive tradition 2D Cardiac imaging as ordered per standard of care. Then, the participant will receive a 4D image, requiring 6 to 10 additional minutes in the MRI scanner. The 2D and 4D images will be interpreted by readers blinded to the results of the alternate modality. Inter- and intra-reader reliability will be assessed.","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":250,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"All Enrollees","type":"EXPERIMENTAL","description":"Intervention: Diagnostic test\n\nAll enrollees will receive a 4D MRI as a research intervention using imaging software for 4 dimensional images for Cardiac MRI","interventionNames":["Device: Imaging software for 4 dimensional images for Cardiac MRI"]}],"interventions":[{"type":"DEVICE","name":"Imaging software for 4 dimensional images for Cardiac MRI","description":"All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI","armGroupLabels":["All Enrollees"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"2D imaging findings and medical diagnoses resulting from images.","description":"Investigators will count the number of study outcomes documented that are related to patient treatment.","timeFrame":"Investigators are expected to interpret the 2D images in one sitting requiring 15 minutes to three hours, depending on exam complexity. The investigator will complete the scan review within 1 day to 1 month of the exam date."},{"measure":"4D imaging findings and medical diagnoses resulting from images.","description":"Investigators will count the number of study outcomes documented that are related to patient treatment.","timeFrame":"Investigators are expected to interpret the 4D images in one sitting requiring 15 minutes to three hours, depending on exam complexity. The investigator will complete the scan review within 1 day to 1 month of the exam date."}],"secondaryOutcomes":[{"measure":"2D Time to scan acquisition","description":"Investigators will document time to acquire 2D image.","timeFrame":"The 2D scan time will be from the time the 2D patient scan starts to the time the 2D patient scan ends. These will be measured on the patient's scheduled scan date."},{"measure":"Time to 2D scan interpretation","description":"Time to interpret 2-D scan interpretation will be from the time the reader starts reading the 2D scan until the time the reader finishes reading the 2D scan.","timeFrame":"The time required for the reader to interpret scan for 2D and to document results. Within one month of scan completion. Reader is expected to interpret each scan in 1 to 3 hours."},{"measure":"Intra-reader reliability","description":"Each reader will read each scan assigned on two different dates. The reader will be blind to identity of scan. The two readings will be compared for consistency.","timeFrame":"The reader will record all findings from each scan immediately upon completion of scan interpretation. Findings should be recorded within a month of the exam."},{"measure":"Image quality","description":"Overall measure of all scan image quality based on standard quality assessment protocol definitions.","timeFrame":"The reader will record an image score for each exam during interpretation of the scan. The reader will record an image score within one month of scan completion date."},{"measure":"2D patient recommended treatments","description":"The reader will document recommendations for patient treatment based on 2D imaging results","timeFrame":"The reader will recommend follow-up patient care for each patient based upon completion of the exam interpretation. The reader will record all recommendations within one month of the exam."},{"measure":"90 day follow up","description":"Describe patient follow-up. The interviewer will record the patient follow up by interviewing the patient within 90 to 120 days of the scan and asking what follow up was taken; and by medical record review. Follow up will be recorded and will be compared to recommended follow up.","timeFrame":"The interviewer will contact patients with a target date of 90 to 120 days after the exam to obtain the followup information via telephone."},{"measure":"4D Time to scan acquisition","description":"Investigators will document time to acquire 4D image","timeFrame":"The 4D scan time will be from the time the 4D patient scan starts to the time the 4D patient scan ends. These will be measured on the patients scheduled scan date."},{"measure":"Time to 4D scan interpretation","description":"Time to interpret 4D scan interpretation will be from the time the reader starts reading the 4D scan until the time the reader finishes reading the 4D scan.","timeFrame":"The time required for the reader to interpret scan for 4D and to document results. Within one month of scan completion. Reader is expected to interpret each scan in 1 to 3 hours."},{"measure":"Inter-reader reliability","description":"Two readers will read each scan. The readers will be blind to identity of scan. the reader will not know the results reported by the second reader. The two readings will be compared for consistency.","timeFrame":"The reader will record all findings from each scan immediately upon completion of scan interpretation. Findings should be recorded within a month of the exam."},{"measure":"4D patient recommended treatments","description":"The reader will document recommendations for patient treatment based on 4D imaging results","timeFrame":"The reader will recommend follow-up patient care for each patient based upon completion of the exam interpretation. The reader will record all recommendations within one month of the exam."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years of age or older\n* with a valid prescription for Cardiac MRI for the following: Congenital heart disease/Shunts, Valvular heart disease, Pulmonary Hypertension, Aortic Disease, Hypertrophic Cardiomyopathy (HCM)\n* receiving Standard of Care services at the MRI Center\n* consent to participate in the 4D trial\n\nExclusion Criteria:\n\nPatients with any of the following will be excluded:\n\n* Pacemaker or ICD implanted\n* ICDs implanted\n* Temporary Pacemakers (e.g. transvenous temporary wires)\n* Leads that are abandoned (capped or retained leads not attached to device)\n* Non-transvenous leads (e.g. epicardial leads)\n* Leads that have no fixation (e.g. floating leads)\n* A lead that is known to be fractured\n* Any other metallic objects that, in the opinion of the safety officer would compromise patient safety","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Michael Poon, MD","affiliation":"Northwell Health","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Northwell Health Imaging at Greenwich Village: a Division of Lenox Hill Hospital","city":"New York","state":"New York","zip":"10011","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}}]},"referencesModule":{"references":[{"pmid":"6833669","type":"BACKGROUND","citation":"Okada RD, Lim YL, Rothendler J, Boucher CA, Block PC, Pohost GM. Split dose thallium-201 dipyridamole imaging: a new technique for obtaining thallium images before and immediately after an intervention. J Am Coll Cardiol. 1983 May;1(5):1302-10. doi: 10.1016/s0735-1097(83)80144-2. No abstract available."},{"pmid":"25708923","type":"BACKGROUND","citation":"Vasanawala SS, Hanneman K, Alley MT, Hsiao A. Congenital heart disease assessment with 4D flow MRI. J Magn Reson Imaging. 2015 Oct;42(4):870-86. doi: 10.1002/jmri.24856. Epub 2015 Feb 24."},{"pmid":"21221566","type":"BACKGROUND","citation":"Hsiao A, Alley MT, Massaband P, Herfkens RJ, Chan FP, Vasanawala SS. Improved cardiovascular flow quantification with time-resolved volumetric phase-contrast MRI. Pediatr Radiol. 2011 Jun;41(6):711-20. doi: 10.1007/s00247-010-1932-z. Epub 2011 Jan 11."},{"pmid":"22358022","type":"BACKGROUND","citation":"Hsiao A, Lustig M, Alley MT, Murphy M, Chan FP, Herfkens RJ, Vasanawala SS. Rapid pediatric cardiac assessment of flow and ventricular volume with compressed sensing parallel imaging volumetric cine phase-contrast MRI. AJR Am J Roentgenol. 2012 Mar;198(3):W250-9. doi: 10.2214/AJR.11.6969."},{"pmid":"22923717","type":"BACKGROUND","citation":"Hsiao A, Lustig M, Alley MT, Murphy MJ, Vasanawala SS. Evaluation of valvular insufficiency and shunts with parallel-imaging compressed-sensing 4D phase-contrast MR imaging with stereoscopic 3D velocity-fusion volume-rendered visualization. Radiology. 2012 Oct;265(1):87-95. doi: 10.1148/radiol.12120055. Epub 2012 Aug 24."},{"pmid":"25790878","type":"BACKGROUND","citation":"Uretsky S, Gillam L, Lang R, Chaudhry FA, Argulian E, Supariwala A, Gurram S, Jain K, Subero M, Jang JJ, Cohen R, Wolff SD. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. J Am Coll Cardiol. 2015 Mar 24;65(11):1078-88. doi: 10.1016/j.jacc.2014.12.047."},{"pmid":"26257141","type":"BACKGROUND","citation":"Dyverfeldt P, Bissell M, Barker AJ, Bolger AF, Carlhall CJ, Ebbers T, Francios CJ, Frydrychowicz A, Geiger J, Giese D, Hope MD, Kilner PJ, Kozerke S, Myerson S, Neubauer S, Wieben O, Markl M. 4D flow cardiovascular magnetic resonance consensus statement. J Cardiovasc Magn Reson. 2015 Aug 10;17(1):72. doi: 10.1186/s12968-015-0174-5."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13","submissionTracking":{"estimatedResultsFirstSubmitDate":"2022-12-15","submissionInfos":[{"releaseDate":"2022-12-15","resetDate":"2023-01-10","mcpReleaseN":9},{"releaseDate":"2023-04-17","resetDate":"2023-05-09","mcpReleaseN":10}]}},"conditionBrowseModule":{"meshes":[{"id":"D006331","term":"Heart Diseases"}],"ancestors":[{"id":"D002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M9419","name":"Heart Diseases","asFound":"Cardiac Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06149143","orgStudyIdInfo":{"id":"CPS_MINNESOTA"},"organization":{"fullName":"Sensydia Corporation","class":"INDUSTRY"},"briefTitle":"Cardiac Performance System Data Collection Study - Minnesota","officialTitle":"Cardiac Performance System Data Collection Study - Minnesota"},"statusModule":{"statusVerifiedDate":"2024-04","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-10-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-06-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-11-20","studyFirstSubmitQcDate":"2023-11-20","studyFirstPostDateStruct":{"date":"2023-11-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-04-15","lastUpdatePostDateStruct":{"date":"2024-04-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sensydia Corporation","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Non-significant risk device study to conduct evaluation of the performance of new device for monitoring of cardiac function (based on previous iterations 510(k) 173156)","detailedDescription":"Non-significant risk device study to conduct evaluation of the performance of new device for monitoring of cardiac function (based on previous iterations 510(k) 173156)"},"conditionsModule":{"conditions":["Cardiac Disease"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":50,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cardiac Function Monitoring","description":"Subjects scheduled for cardiac catheterization will undergo measurement with the Cardiac Performance System non-invasive device for a brief period before the catheterization procedure.","interventionNames":["Device: Cardiac Performance System (NSR)"]}],"interventions":[{"type":"DEVICE","name":"Cardiac Performance System (NSR)","description":"Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.","armGroupLabels":["Cardiac Function Monitoring"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Cardiac Performance System electronic data for Cardiac Output","description":"Cardiac function metric measurement including Cardiac Output to report in L/m.","timeFrame":"10 minutes before cardiac catheterization procedure"},{"measure":"Cardiac Performance System electronic data for Pulmonary Artery Pressure","description":"Cardiac function metric measurement including Pulmonary Artery Pressure to report in mmHg.","timeFrame":"10 minutes before cardiac catheterization procedure"},{"measure":"Cardiac Performance System electronic data for Pulmonary Capillary Wedge Pressure","description":"Cardiac function metric measurement including Pulmonary Capillary Wedge Pressure to report in mmHg.","timeFrame":"10 minutes before cardiac catheterization procedure"},{"measure":"Pulmonary Artery Catheter electronic data for Cardiac Output","description":"Cardiac function metric measurement including Cardiac Output to report in L/m.","timeFrame":"60 minutes during cardiac catheterization procedure"},{"measure":"Pulmonary Artery Catheter electronic data for Pulmonary Artery Pressure","description":"Cardiac function metric measurement including Pulmonary Artery Pressure to report in mmHg.","timeFrame":"60 minutes during cardiac catheterization procedure"},{"measure":"Pulmonary Artery Catheter electronic data for Pulmonary Capillary Wedge Pressure","description":"Cardiac function metric measurement including Pulmonary Capillary Wedge Pressure to report in mmHg.","timeFrame":"60 minutes during cardiac catheterization procedure"},{"measure":"Echocardiography electronic data for Ejection Fraction","description":"Cardiac function measurement including left ventricle ejection fraction to report in percentage.","timeFrame":"15 minutes at a time prior to or after Pulmonary Artery Catheter procedure"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ability to provide written informed consent\n* 22 years of age or older\n* Referred for cardiac catheterization for reasons including heart failure, evaluation before transplant, pulmonary hypertension, shortness of breath, valvular disease, etc.\n\nExclusion Criteria:\n\n* Previous Heart Transplant\n* Presence of Left Ventricular Assist Device\n* Presence of a Holter monitor or any other electrical leads on the chest at the time of sensor placement\n* Surgical scars/wounds/bandages/ports at the site of sensor placement","healthyVolunteers":true,"sex":"ALL","minimumAge":"22 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients scheduled for cardiac catheterization procedure","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Sensydia","role":"CONTACT","phone":"6618774670","email":"info[@]sensydia.com"}],"locations":[{"facility":"University of Minnesota","status":"RECRUITING","city":"Minneapolis","state":"Minnesota","zip":"55455","country":"United States","contacts":[{"name":"Tamas Alexy","role":"CONTACT"}],"geoPoint":{"lat":44.97997,"lon":-93.26384}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D006331","term":"Heart Diseases"}],"ancestors":[{"id":"D002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M9419","name":"Heart Diseases","asFound":"Cardiac Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05866666","orgStudyIdInfo":{"id":"CPS_ORLANDO"},"organization":{"fullName":"Sensydia Corporation","class":"INDUSTRY"},"briefTitle":"Cardiac Performance System Data Collection Study","officialTitle":"Cardiac Performance System Data Collection Study"},"statusModule":{"statusVerifiedDate":"2023-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-05-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-05-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-05-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-05-10","studyFirstSubmitQcDate":"2023-05-10","studyFirstPostDateStruct":{"date":"2023-05-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-11-20","lastUpdatePostDateStruct":{"date":"2023-11-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sensydia Corporation","class":"INDUSTRY"},"collaborators":[{"name":"Orlando Health, Inc.","class":"OTHER"}]},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Non-significant risk device study to conduct evaluation of the performance of new device for monitoring of cardiac function (based on previous iterations 510(k) 173156)","detailedDescription":"Non-significant risk device study to conduct evaluation of the performance of new device for monitoring of cardiac function (based on previous iterations 510(k) 173156)"},"conditionsModule":{"conditions":["Cardiac Disease"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":115,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cardiac Function Monitoring","description":"Subjects scheduled for cardiac catheterization will undergo measurement with the Cardiac Performance System non-invasive device for a brief period before the catheterization procedure.","interventionNames":["Device: Cardiac Performance System (NSR)"]}],"interventions":[{"type":"DEVICE","name":"Cardiac Performance System (NSR)","description":"Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.","armGroupLabels":["Cardiac Function Monitoring"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Cardiac Performance System electronic data for Cardiac Output","description":"Cardiac function metric measurement including Cardiac Output to report in L/m.","timeFrame":"10 minutes before cardiac catheterization procedure"},{"measure":"Cardiac Performance System electronic data for Pulmonary Artery Pressure","description":"Cardiac function metric measurement including Pulmonary Artery Pressure to report in mmHg.","timeFrame":"10 minutes before cardiac catheterization procedure"},{"measure":"Cardiac Performance System electronic data for Pulmonary Capillary Wedge Pressure","description":"Cardiac function metric measurement including Pulmonary Capillary Wedge Pressure to report in mmHg.","timeFrame":"10 minutes before cardiac catheterization procedure"},{"measure":"Pulmonary Artery Catheter electronic data for Cardiac Output","description":"Cardiac function metric measurement including Cardiac Output to report in L/m.","timeFrame":"60 minutes during cardiac catheterization procedure"},{"measure":"Pulmonary Artery Catheter electronic data for Pulmonary Artery Pressure","description":"Cardiac function metric measurement including Pulmonary Artery Pressure to report in mmHg.","timeFrame":"60 minutes during cardiac catheterization procedure"},{"measure":"Pulmonary Artery Catheter electronic data for Pulmonary Capillary Wedge Pressure","description":"Cardiac function metric measurement including Pulmonary Capillary Wedge Pressure to report in mmHg.","timeFrame":"60 minutes during cardiac catheterization procedure"},{"measure":"Echocardiography electronic data for Ejection Fraction","description":"Cardiac function measurement including left ventricle ejection fraction to report in percentage.","timeFrame":"15 minutes at a time prior to or after Pulmonary Artery Catheter procedure"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ability to provide written informed consent\n* 22 years of age or older\n* Referred for cardiac catheterization for reasons including heart failure, evaluation before transplant, pulmonary hypertension, shortness of breath, valvular disease, etc.\n\nExclusion Criteria:\n\n* Previous Heart Transplant\n* Presence of Left Ventricular Assist Device\n* Presence of a Holter monitor or any other electrical leads on the chest at the time of sensor placement\n* Surgical scars/wounds/bandages/ports at the site of sensor placement","healthyVolunteers":true,"sex":"ALL","minimumAge":"22 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients scheduled for cardiac catheterization procedure","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Sensydia","role":"CONTACT","phone":"6618774670","email":"info@sensydia.com"}],"overallOfficials":[{"name":"Yahaira Ortiz-Gonzalez, MD","affiliation":"Orlando Health","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Orlando Health","status":"RECRUITING","city":"Orlando","state":"Florida","zip":"32806","country":"United States","contacts":[{"name":"Yahaira Ortiz-Gonzalez, MD","role":"CONTACT","phone":"321-843-9657"}],"geoPoint":{"lat":28.53834,"lon":-81.37924}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D006331","term":"Heart Diseases"}],"ancestors":[{"id":"D002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M9419","name":"Heart Diseases","asFound":"Cardiac Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT04804969","orgStudyIdInfo":{"id":"HS-CLINVAL-001"},"organization":{"fullName":"Heart Test Laboratories, Inc.","class":"INDUSTRY"},"briefTitle":"MyoVista wavECG Clinical Validation Study Versus Low e' on Echocardiogram","officialTitle":"MyoVista wavECG Clinical Validation Study"},"statusModule":{"statusVerifiedDate":"2023-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-05-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-11-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-11-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-03-16","studyFirstSubmitQcDate":"2021-03-16","studyFirstPostDateStruct":{"date":"2021-03-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-09-20","lastUpdatePostDateStruct":{"date":"2023-09-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Heart Test Laboratories, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUnapprovedDevice":true,"isUsExport":false},"descriptionModule":{"briefSummary":"Clinical validation study of the MyoVista wavECG.","detailedDescription":"This is a multi-center, non-interventional, single arm clinical study of the MyoVista wavECG for the detection of LV relaxation abnormalities. Study subjects will be drawn from patients who are at-risk for cardiac disease and who have been referred for 2D transthoracic echocardiogram.\n\nThe study will be conducted at a minimum of three investigational sites within the United States."},"conditionsModule":{"conditions":["Cardiac Disease"],"keywords":["Left Ventricular Diastolic Dysfunction","Electrocardiograph"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":575,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"At Risk Echo Referrals","description":"Study subjects will be drawn from patients who are at-risk for cardiac disease and who have been referred for 2D transthoracic echocardiogram as standard of care. All will receive a MyoVista wavECG test.","interventionNames":["Device: MyoVista wavECG Test"]}],"interventions":[{"type":"DEVICE","name":"MyoVista wavECG Test","description":"The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.","armGroupLabels":["At Risk Echo Referrals"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Sensitivity and Specificity","description":"Sensitivity and specificity of the MyoVista for the classification of Low e' from echocardiogram where a \"positive\" includes Positive and Highly Positive MyoVista Device outcomes.","timeFrame":"Baseline"}],"secondaryOutcomes":[{"measure":"Sensitivity and Specificity","description":"Sensitivity and specificity of the MyoVista for classification of Low e' versus echocardiogram where a \"positive\" includes Borderline, Positive and Highly Positive MyoVista Device outcomes.","timeFrame":"Baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with risk factors for cardiac disease or suspected of having cardiac disease during clinical assessment.\n* The subject provides written informed consent using an Informed Consent Form that is reviewed and approved by the site's Institutional Review Board (IRB).\n* Conventional ECG results show a sinus rhythm and no other contraindicated rhythm abnormalities (see exclusions below).\n* Subject is \\>/= 22 years of age\n\nExclusion Criteria:\n\n* The subject has current acute coronary syndrome, decompensated heart failure or stroke\n* The subject has received any prior cardiac interventions or surgical therapeutic procedures relating to cardiac abnormalities: valve replacement, pacemaker implantation, coronary artery bypass grafting (CABG), heart transplant, ablation, coronary stent placement, etc.\n* Conventional ECG results indicating a lack of sinus rhythm and/or any other contraindicated rhythm abnormalities, including: active atrial fibrillation or atrial flutter, left anterior fascicular block, left and/or right bundle branch block\n* The subject is pregnant at the time of the study testing\n* The subject has chest deformities that interfere with accurate measurement of ECG (either conventional or wavECG)\n* Subjects with central nervous system or musculoskeletal abnormalities that may interfere with accurate acquisition of ECG and/or echocardiogram measurements.\n* The subject is enrolled in another clinical study that may interfere with MyoVista or echocardiogram measurements. Exceptions to this may be approved by HeartSciences.","healthyVolunteers":false,"sex":"ALL","minimumAge":"22 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Subjects with risk factors for cardiac disease or suspected of having cardiac disease during clinical assessment and have been referred to the site for 2D transthoracic echocardiogram.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Partho Sengupta, MD","affiliation":"Robert Wood Johnson University Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Scripps Memorial Hospital","city":"La Jolla","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Beth Israel Deaconess Medical Center","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Montefiore Medical Center","city":"Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Einstein Medical Center","city":"Philadelphia","state":"Pennsylvania","zip":"19141","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"University of Texas Southwestern Medical Center","city":"Dallas","state":"Texas","zip":"75204","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D006331","term":"Heart Diseases"}],"ancestors":[{"id":"D002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M9419","name":"Heart Diseases","asFound":"Cardiac Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05408260","orgStudyIdInfo":{"id":"19D.799"},"organization":{"fullName":"Thomas Jefferson University","class":"OTHER"},"briefTitle":"A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer","officialTitle":"Feasibility of Automated Breast Ultrasound (ABUS) Versus Handheld Ultrasound (HHUS) for Breast Cancer Surveillance in Women With Nipple Sparing or Skin Sparing Mastectomy With Reconstruction"},"statusModule":{"statusVerifiedDate":"2024-08","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-11-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-08","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-06-02","studyFirstSubmitQcDate":"2022-06-02","studyFirstPostDateStruct":{"date":"2022-06-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-08-01","lastUpdatePostDateStruct":{"date":"2024-08-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Thomas Jefferson University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This clinical trial evaluates automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) for the screening of women who have undergone breast reconstruction after breast cancer. Ultrasounds use high-frequency sound waves to create pictures of internal organs and tissues. ABUS has been found to be equal to HHUS for whole breast screening, but no data exist on its use for screening of reconstructed patients. This clinical trial evaluates the feasibility of using ABUS versus HHUS to screen women who have undergone reconstruction.","detailedDescription":"PRIMARY OBJECTIVE:\n\nI. To show that ABUS reduces artifact compared to HHUS in terms of detection of the residual tissue in reconstructed nipple sparing mastectomy (NSM) and skin sparing mastectomy (SSM) patients.\n\nSECONDARY OBJECTIVES:\n\nI. To evaluate both the performance and interpretation times for ABUS and HHUS so that these factors can be considered when scheduling patients and for ease of implementation into practice.\n\nII. A short survey will be administered immediately after both ultrasounds performed to enrolled patients to assess their experience with HHUS and ABUS, specifically addressing their perceived comfort level on a numerical scale and if they would be interested in obtaining subsequent annual screening HHUS or ABUS.\n\nEXPLORATORY OBJECTIVE:\n\nI. The appearance of native and reconstructed anatomy on ABUS and HHUS will be studied.\n\nOUTLINE:\n\nParticipants undergo HHUS and ABUS in no required order over 1 hour.\n\nParticipants with ultrasound results indicating Breast Imaging Reporting and Data System (BI-RADS) 4 or 5 (suspicious and needs biopsy) undergo biopsy within 30 days."},"conditionsModule":{"conditions":["Malignant Breast Neoplasm"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"SCREENING","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Screening (automated breast ultrasound, handheld ultrasound)","type":"EXPERIMENTAL","description":"Participants undergo HHUS and ABUS in no required order over 1 hour.","interventionNames":["Procedure: Ultrasonography","Procedure: Automated Breast Ultrasound"]}],"interventions":[{"type":"PROCEDURE","name":"Ultrasonography","description":"Undergo HHUS","armGroupLabels":["Screening (automated breast ultrasound, handheld ultrasound)"]},{"type":"PROCEDURE","name":"Automated Breast Ultrasound","description":"Undergo ABUS","armGroupLabels":["Screening (automated breast ultrasound, handheld ultrasound)"],"otherNames":["ABUS"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Detection of the residual tissue (i.e., artifact) in reconstructed nipple sparing mastectomy (NSM) and skin sparing mastectomy (SSM) patients by automated breast ultrasound (ABUS) and handheld ultrasound (HHUS)","description":"This is a binary endpoint. The rate of artifact will be compared between handheld and automated scanning using McNemar test.","timeFrame":"Up to 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female\n* \\>= 18 years of age at time of consent\n* Free of focal breast symptoms and with no suspicious breast physical exam findings\n* Previous unilateral NSM or SSM with implant (silicone, saline) or flap reconstruction performed at Thomas Jefferson University Hospital\n* Must be able to understand and provide signed and dated informed consent form. If a patient understands the informed consent but is unable to sign, a legally authorized representative (LAR) may sign\n* Willing to comply with all study procedures and be available for the duration of the study\n* Willing to honor any bills that may be incurred if the insurance company does not pay for the billed bilateral hand held ultrasound\n\nExclusion Criteria:\n\n* History of breast cancer recurrence\n* Current focal breast symptoms since NSM or SSM with reconstruction\n* NSM or SSM with reconstruction was performed years prior to study enrollment\n* Bilateral NSM or SSM with reconstruction\n* Females who are pregnant","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Sidney Kimmel Cancer Center at Thomas Jefferson University","status":"RECRUITING","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","contacts":[{"name":"Lisa Zorn, MD","role":"CONTACT","phone":"215-955-2811","email":"Lisa.Zorn@jefferson.edu"}],"geoPoint":{"lat":39.95233,"lon":-75.16379}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Breast Neoplasms","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT02340468","orgStudyIdInfo":{"id":"20141505"},"organization":{"fullName":"University of California, Irvine","class":"OTHER"},"briefTitle":"Breast Tumor Oxygenation During Exercise","officialTitle":"Breast Tumor Oxygenation During Exercise"},"statusModule":{"statusVerifiedDate":"2022-10","overallStatus":"WITHDRAWN","whyStopped":"Not clinical trial","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-04"},"primaryCompletionDateStruct":{"date":"2018-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2018-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-01-13","studyFirstSubmitQcDate":"2015-01-13","studyFirstPostDateStruct":{"date":"2015-01-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2022-10-28","lastUpdatePostDateStruct":{"date":"2022-11-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Beckman Laser Institute and Medical Center","investigatorTitle":"Bruce Tromberg,Ph.D.,Director, Beckman Laser Institute and Medical Clinic and Professor, Departments of Biomedical Engineering and Surgery","investigatorAffiliation":"University of California, Irvine"},"leadSponsor":{"name":"University of California, Irvine","class":"OTHER"},"collaborators":[{"name":"Beckman Laser Institute University of California Irvine","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"In the field of cancer treatment, it is generally accepted that the enhancement of oxygen delivery to tumors can augment the effect of anti-cancer therapies. In the case of chemotherapy, this enhancement might lead to a larger amount of a given dose of treatment reaching the tumor and having an effect.","detailedDescription":"While the benefits of exercise on overall health are widely documented, little is known about how exercise affects the progression or treatment of malignant neoplasms. Tumors have a complex vascular network which is likely affected by the global changes in hemodynamics and perfusion that occur during moderate exercise. Increased tumor oxygenation is clinically relevant as it may counteract the hypoxic tumor environment which is known to contribute to resistance to chemo- and radiation therapies, angiogenesis, invasiveness and metastasis, genomic instability, and resistance to cell death.\n\nThe researcher can use noninvasive optical imaging technology called diffuse optical spectroscopy to safely and non-invasively quantify the dynamics of blood flow and metabolism in tumors and normal tissue of subjects undergoing supervised cycling exercise. The researcher can determine that exercise will measurably increase tumor oxygenation, and that this effect will be proportional to the intensity and/or duration of the exercise performed."},"conditionsModule":{"conditions":["Breast Tumor"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_CONTROL","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"interventions":[{"type":"DEVICE","name":"diffuse optical spectroscopy","description":"diffuse optical spectroscopy"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Measure breast tumor oxygenation","timeFrame":"up to 12 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Tumor group, female, Greater than 21 years of age but less than 70 years of age, Current diagnosis of breast cancer stage 0 - IV or radiologically suspicious for breast cancer BI-RADS score 4 or 5.\n* Control group,Female, Greater than 21 years of age but less than 70 years of age, Not currently diagnosed with breast cancer\n\nExclusion Criteria:\n\n* Under 21 years of age, Pregnant or breastfeeding, Contraindications for moderate exercise, history of heart, pulmonary, or musculoskeletal disease; physician instructions to restrict physical activity.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"21 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Study population will be recruited from an outpatient at UC Irvine Health","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bruce Tromberg, PhD","affiliation":"Beckman Laser Institute","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Beckman Laser Institute Medical Clinic","city":"Irvine","state":"California","zip":"92612","country":"United States","geoPoint":{"lat":33.66946,"lon":-117.82311}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Breast Tumor","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT04692818","orgStudyIdInfo":{"id":"20-010751"},"secondaryIdInfos":[{"id":"W81XWH-21-1-0063","type":"OTHER_GRANT","domain":"Department of Defense"}],"organization":{"fullName":"Mayo Clinic","class":"OTHER"},"briefTitle":"3D Ultrasound Breast Imaging","officialTitle":"3D Multimodal Ultrasound Imaging for Breast Cancer"},"statusModule":{"statusVerifiedDate":"2024-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-11-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-12-30","studyFirstSubmitQcDate":"2020-12-30","studyFirstPostDateStruct":{"date":"2021-01-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-12-19","lastUpdatePostDateStruct":{"date":"2024-12-24","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Mayo Clinic","class":"OTHER"},"collaborators":[{"name":"United States Department of Defense","class":"FED"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUsExport":false},"descriptionModule":{"briefSummary":"The purpose of this research is to study the efficacy of a new ultrasound imaging method for diagnosis of breast mass."},"conditionsModule":{"conditions":["Breast Tumor"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"HEALTH_SERVICES_RESEARCH","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":125,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Clinically indicated breast tumor biopsy","type":"EXPERIMENTAL","description":"Subjects with breast lesion and are scheduled for clinically-indicated biopsy will have 3D Multimodal Ultrasound Imaging performed","interventionNames":["Diagnostic Test: GE Logiq E10 clinical ultrasound scanner","Diagnostic Test: Verasonics research scanner"]}],"interventions":[{"type":"DIAGNOSTIC_TEST","name":"GE Logiq E10 clinical ultrasound scanner","description":"2D B-mode, Doppler, and shear wave elastography images of the lesion","armGroupLabels":["Clinically indicated breast tumor biopsy"]},{"type":"DIAGNOSTIC_TEST","name":"Verasonics research scanner","description":"3D B-mode imaging, microvessel imaging, and shear wave elastography","armGroupLabels":["Clinically indicated breast tumor biopsy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"BI-RADS Score","description":"BI-RADS scores will be obtained using 2D B-mode ultrasound images from the GE Logiq E10 clinical scanner, and using 3D B-mode images from the Verasonics scanner. A 7-point BI-RADS scale will be used, with a score of 1, 2, or 3 considered negative and 4a, 4b, 4c, and 5 considered positive.","timeFrame":"Baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult women  18 years of age.\n* solid breast lesion and ultrasound guided biopsy (either as part of their clinical care or through participation in other IRB-approved studies)\n* lesion size of 3mm or larger\n\nExclusion Criteria:\n\n* \\< 18 years of age.\n* Lacking capacity to consent\n* Pregnant or lactating\n* Receiving cancer therapy such as chemotherapy or radiation therapy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Bobbie Ott","role":"CONTACT","phone":"507-293-0922","email":"Ott.Bobbie@mayo.edu"}],"overallOfficials":[{"name":"Shigao Chen, PhD","affiliation":"Mayo Clinic","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Christine Lee, MD, PhD","affiliation":"Mayo Clinic in Rochester","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Mayo Clinic in Rochester","status":"RECRUITING","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","contacts":[{"name":"Rica Pol","role":"CONTACT","phone":"507-422-5118","email":"Pol.Hanarica@mayo.edu"},{"name":"Shigao Chen, PhD","role":"CONTACT"},{"name":"Christine lee, MD, PhD","role":"CONTACT"}],"geoPoint":{"lat":44.02163,"lon":-92.4699}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Mayo Clinic Clinical Trials","url":"https://www.mayo.edu/research/clinical-trials"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Breast Tumor","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT02725658","orgStudyIdInfo":{"id":"20152355"},"organization":{"fullName":"University of California, Irvine","class":"OTHER"},"briefTitle":"Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI","officialTitle":"Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting"},"statusModule":{"statusVerifiedDate":"2022-10","overallStatus":"WITHDRAWN","whyStopped":"This study doesn't meet NIH criteria of clinical trial study","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-12"},"primaryCompletionDateStruct":{"date":"2019-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2019-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2016-01-29","studyFirstSubmitQcDate":"2016-03-28","studyFirstPostDateStruct":{"date":"2016-04-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2022-10-28","lastUpdatePostDateStruct":{"date":"2022-11-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Beckman Laser Institute and Medical Center","investigatorTitle":"Bruce Tromberg, PhD, Director Beckman Laser Institute and Medical Clinic, Professor, Departments of Biomedical Engineering and Surgery","investigatorAffiliation":"University of California, Irvine"},"leadSponsor":{"name":"Beckman Laser Institute and Medical Center","class":"OTHER"},"collaborators":[{"name":"Beckman Laser Institute University of California Irvine","class":"OTHER"},{"name":"University of California, San Francisco","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this research study is to help us learn if an experimental imaging device called Diffuse Optical Spectroscopic Imaging (DOSI) can monitor tumor shrinkage during chemotherapy treatment and can predict if the tumor will respond to chemotherapy before the end of the treatment. This study will also help us understand the biological reason for how DOSI works.","detailedDescription":"There is considerable interest in developing imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy (NAC), which is chemotherapy given before surgical removal of the tumor, both prior to and as early as possible during the course of treatment. The efficacy and practicality of conventional imaging approaches in the NAC setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging (DOSI) is an experimental imaging method that allows patients to be followed before and during treatment with a cost-effective, bedside, handheld scanning probe. DOSI is a non-invasive technology developed at the University of California, Irvine Beckman Laser Institute. Studies will be performed at seven clinical sites on approximately 200 suspected breast cancer patients, of which 150 are expected to undergo neoadjuvant chemotherapy (NAC).\n\nAs a primary aim, the investigators will evaluate whether DOSI can predict NAC pathologic complete response (pCR), which is defined as no tumor cell left in the resected tissue at surgery) by the mid-point of the therapy regimen. As non-invasive DOSI is obtained rapidly with no risk/discomfort, this experimental imaging modality could be used as an indicator of pathologic response which has been an established indicator of long-term survival. The investigators long-term goal is to provide oncologists with a relatively simple, risk-free bedside tool that can be used to help inform medical decisions on chemotherapy regimen, duration, and timing of surgery, thereby maximizing therapeutic response and minimizing unnecessary toxicity."},"conditionsModule":{"conditions":["Breast Tumor"],"keywords":["Neoadjuvant Therapy","Diffuse Optical Spectroscopic Imaging","DOSI","Neoadjuvant Chemotherapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"HEALTH_SERVICES_RESEARCH","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"DOSI","type":"OTHER","interventionNames":["Device: DOSI"]}],"interventions":[{"type":"DEVICE","name":"DOSI","description":"Breast tissue properties scanning","armGroupLabels":["DOSI"],"otherNames":["Diffuse Optical Spectroscopy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Concentration of oxy-hemoglobin (HbO2), in blood.","timeFrame":"through study completion, an average of 3 years"},{"measure":"Concentration of deoxy-hemoglobin (HHb) in blood.","timeFrame":"through study completion, an average of 3 years"},{"measure":"Concentration of total hemoglobin in blood.","timeFrame":"through study completion, an average of 3 years"},{"measure":"Water content of tissue (%)","timeFrame":"through study completion, an average of 3 years"},{"measure":"Bulk lipid in tissue (%)","timeFrame":"through study completion, an average of 3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Females between the ages of 21 and 80. Specific to Study part #1\n* Diagnosed with a Breast Imaging-Reporting and Data System score of 4 or higher breast abnormality greater than 1cm in size Specific to Study part #2\n* Enrolled in study part #1\n* Diagnosed with histologically-proven invasive breast cancer\n* Prescribed neoadjuvant chemotherapy for breast cancer\n\nExclusion Criteria:\n\n* Pregnant\n* Unable to give written, informed consent.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"21 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bruce J Tromberg, PhD","affiliation":"Beckman Laser Institute","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Pacific Breast Care Clinic","city":"Costa Mesa","state":"California","zip":"92627","country":"United States","geoPoint":{"lat":33.64113,"lon":-117.91867}},{"facility":"Beckman Laser Institute University of California Irvine","city":"Irvine","state":"California","zip":"92612","country":"United States","geoPoint":{"lat":33.66946,"lon":-117.82311}},{"facility":"University of California, Irvine Medical Center","city":"Irvine","state":"California","zip":"92612","country":"United States","geoPoint":{"lat":33.66946,"lon":-117.82311}},{"facility":"University of California San Francisco","city":"San Francisco","state":"California","zip":"94110","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Breast Tumor","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT03463954","orgStudyIdInfo":{"id":"BR-003"},"organization":{"fullName":"Novian Health Inc.","class":"INDUSTRY"},"briefTitle":"Confirmatory Clinical Evaluation of Novilase Laser Therapy for Focal Destruction of Malignant Breast Tumors","officialTitle":"Prospective, Multicenter Confirmatory Clinical Evaluation of Novilase Interstitial Laser Therapy for the Focal Destruction of Malignant Breast Tumors 15 mm (BR-003)"},"statusModule":{"statusVerifiedDate":"2024-04","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-08-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-09-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-09-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2018-01-23","studyFirstSubmitQcDate":"2018-03-06","studyFirstPostDateStruct":{"date":"2018-03-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-04-01","lastUpdatePostDateStruct":{"date":"2024-04-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novian Health Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true},"descriptionModule":{"briefSummary":"Prior to this confirmatory pivotal study, the multicenter Br-002 feasibility study was completed. 98% of tumors less than or equal to 15mm were completely ablated in one procedure.This study will evaluate Novilase for the focal destruction of malignant tumors of the breast that are less than or equal to 15 mm against a performance goal for the standard of care, lumpectomy. The ASBrS' goal of less than 20% retreatment by 2020 was selected as a representative performance goal, i.e., 80.0%, and is consistent with published effectiveness rates for lumpectomy.","detailedDescription":"Subjects with biopsy-diagnosed malignant breast tumors less than or equal to 15 mm will be invited to participate. Subjects will receive a screening MRI and if eligible will then have laser ablation, followed by MRI and an excision at 4-6 weeks following the laser procedure. This study will be deemed successful if the lower limit of a 95% confidence interval for the proportion of patients who have complete tumor ablation with one Novilase laser ablation procedure at 4-6 weeks post-procedure is greater than the performance goal. Specifically, Novilase will have demonstrated success if the complete tumor ablation rate is greater than 87.85%."},"conditionsModule":{"conditions":["Malignant Neoplasm of Breast"],"keywords":["less than or equal to 15 mm"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":122,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Novilase Laser Ablation and excision","type":"EXPERIMENTAL","description":"Eligible subject will receive image-guided laser ablation of a targeted malignant breast tumor. At 4-6 weeks following the ablation, she will receive a MRI and excision. Pathology and MRI will determine rate of complete ablation. Subject is expected to proceed with radiation and/or adjuvant therapy per standard of care.","interventionNames":["Device: Novilase Laser ablation"]}],"interventions":[{"type":"DEVICE","name":"Novilase Laser ablation","description":"Image-guided, percutaneous laser ablation of breast tumors","armGroupLabels":["Novilase Laser Ablation and excision"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of target tumors completely ablated in one procedure","description":"Efficacy: Rate of complete ablation by Novilase laser ablation","timeFrame":"4-6 weeks"},{"measure":"Frequency of adverse events (categorized using the NCI Common Terminology for Adverse Events (CTCAE) v4.0 guidelines) post-laser ablation and post-surgery","description":"Safety: frequency of AEs","timeFrame":"4-6 weeks"}],"secondaryOutcomes":[{"measure":"Patient reported rate of return to activities of daily living post-laser ablation and post-surgery","description":"Rate of recovery","timeFrame":"4-6 weeks"},{"measure":"Physician reported cosmetic satisfaction, utilizing the 4-point scoring system of breast cosmesis in protocol (e.g., excellent, good, fair, poor) post-laser ablation and post-surgery (4-6 weeks)","description":"Post-procedure cosmetic satisfaction","timeFrame":"4-6 weeks"},{"measure":"Health related quality of life outcome measures at three timepoints via EORTC QLQ-C30 & QLQ-BR23 questionnaire (baseline and 4-6 weeks post-laser ablation and post-surgery)","description":"Health-related quality of life outcome measures","timeFrame":"4-6 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Females, aged 18 years and older\n* Able to give written informed consent herself\n* Definitive pathologic diagnosis by needle core biopsy\n* Unifocal malignant tumor (T1a-c, N0-1, M0) that does not exceed 15 mm in longest dimension and measures at least 5 mm away from the skin and chest wall, or can be moved at least 5 mm away from the skin and chest wall by injection of saline or local anesthetic\n* No more than 10 mm of calcifications confined to the tumor on imaging\n* Tumor is well visualized through ultrasound or x-ray mammography imaging and amenable to image-guidance therapy (i.e., a tumor which is well visualized through imaging can be identified from surrounding breast tissue and does not have margins obscured by other structures or artifacts on the images)\n* Tumor is well visualized on MRI\n* Subject with mammographic appearance of overall dense parenchymal tissue may be included, as long as a clearly evident marker is present at tumor site\n* Tumor with less than 25% intraductal component, as determined by core biopsy\n* No clinically significant co-morbidities (e.g., chronic illnesses existing simultaneously with and usually independent of breast cancer) that affect life expectancy\n* Subject weight limited to 300 lbs. or 136 kg\n* Subject agrees to comply with standard of care radiation or adjuvant therapy as prescribed by physician\n\nExclusion Criteria:\n\n* Subject younger than 18 years of age\n* Pregnant or breast-feeding\n* Tumor poorly visualized by ultrasound or x-ray mammography imaging\n* Contraindications to administration of gadolinium-based contrast agent, including: prior allergic reaction to a gadolinium-based contrast agent, moderate to end-stage kidney disease, and/or acute or chronic severe renal insufficiency (Glomerular filtration rate (GFR) \\<30ml/min/1.73 sq. meters)\n* Contraindications to MRI according to site guidelines (e.g., cardiac pacemaker, metallic implants)\n* History of severe asthma\n* Tumor measuring greater than 15 mm in longest dimension\n* Microcalcifications that extend beyond target tumor such that overall longest dimension of target tumor and calcifications is longer than 15 mm.\n* Advanced stage breast cancer\n* Tumors that are lobular neoplasm, metastatic carcinoma to breast, sarcoma, Phyllodes tumor, or Paget's disease\n* Tumor with only DCIS with microinvasion\n* Extensive intraductal component in lesion (i.e., \\>25%) as determined by core biopsy\n* Subject who is known to be BRCA positive\n* Tumor that is ER/PR/HER2 negative (TNBC)\n* Inability to lie in prone or supine position for one hour\n* Subject who is currently participating in another investigational treatment, device or drug study through follow up that would interfere with this trial\n* Subject without a definitive HER2 test according to ASCO/CAP guidelines","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Eugene Bajorinas","role":"CONTACT","phone":"3122667200","email":"ebajorinas@novianhealth.com"},{"name":"Chip Appelbaum","role":"CONTACT","phone":"3122667200","email":"info@novianhealth.com"}],"overallOfficials":[{"name":"John Lewin, MD","affiliation":"Yale University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"City of Hope","status":"RECRUITING","city":"Duarte","state":"California","zip":"91010","country":"United States","contacts":[{"name":"Basak Gokcora","role":"CONTACT","email":"bgokcora@coh.org"},{"name":"Jamie Rand, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Luz Tumyan, MD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"UC San Diego Health","status":"RECRUITING","city":"La Jolla","state":"California","zip":"92037","country":"United States","contacts":[{"name":"Haydee Ojeda-Fournier, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Mohammad Eghtedari, MD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Yale University","status":"RECRUITING","city":"New Haven","state":"Connecticut","zip":"06511","country":"United States","contacts":[{"name":"Kristen DeFrancesco","role":"CONTACT","phone":"203-785-3852","email":"kristin.defrancesco@yale.edu"},{"name":"John Lewin, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Liane Philpotts, MD","role":"SUB_INVESTIGATOR"},{"name":"Liva Andrejeva-Wright, MD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Walter Reed National Military Medical Center","status":"RECRUITING","city":"Bethesda","state":"Maryland","zip":"20889","country":"United States","contacts":[{"name":"Craig Shriver, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Priya Bhandarkar, MD","role":"SUB_INVESTIGATOR"},{"name":"Matthew Nealeigh, DO","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":38.98067,"lon":-77.10026}},{"facility":"Summit Health","status":"NOT_YET_RECRUITING","city":"Florham Park","state":"New Jersey","zip":"07932","country":"United States","contacts":[{"name":"Michelle McKenzie, RN","role":"CONTACT","phone":"973-436-1755","email":"mmackenzie@summithealth.com"},{"name":"Winnie Polen, DO","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.78788,"lon":-74.38821}},{"facility":"Buffalo General Medical Center","status":"RECRUITING","city":"Buffalo","state":"New York","zip":"14203","country":"United States","contacts":[{"name":"Gabriel Rubio","role":"CONTACT","email":"Grubio@gppconline.com"},{"name":"Stuti Tambar, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"St. Elisabeth-Krankenhaus Kln-Hohenlind","status":"RECRUITING","city":"Cologne","zip":"50935","country":"Germany","contacts":[{"name":"Claudia Schumacher, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Heidelberg University Hospital","status":"NOT_YET_RECRUITING","city":"Heidelberg","zip":"69120","country":"Germany","contacts":[{"name":"Joerg Heil, MD, PhD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Breast Centre Zurich","status":"RECRUITING","city":"Zurich","zip":"8008","country":"Switzerland","contacts":[{"name":"Uwe Gth, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Christoph Tausch, MD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":47.36667,"lon":8.54999}},{"facility":"University Hospital Zurich","status":"RECRUITING","city":"Zurich","zip":"8091","country":"Switzerland","contacts":[{"name":"Heike Frauchiger-Heuer, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.36667,"lon":8.54999}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D009369","term":"Neoplasms"},{"id":"D001943","term":"Breast Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Malignant Neoplasm of Breast","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT04426344","orgStudyIdInfo":{"id":"202005150"},"organization":{"fullName":"Washington University School of Medicine","class":"OTHER"},"briefTitle":"Core Warming of COVID-19 Patients","officialTitle":"Core Warming of COVID-19 Patients Undergoing Mechanical Ventilation: a Randomized, Single Center Pilot Study"},"statusModule":{"statusVerifiedDate":"2020-10","overallStatus":"WITHDRAWN","whyStopped":"Internal decision","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-10","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2020-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2020-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-06-03","studyFirstSubmitQcDate":"2020-06-09","studyFirstPostDateStruct":{"date":"2020-06-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-10-14","lastUpdatePostDateStruct":{"date":"2020-10-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Washington University School of Medicine","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a small scale pilot study to evaluate if core warming improves respiratory physiology of mechanically ventilated patients with COVID-19, allowing earlier weaning from ventilation, and greater overall survival. This prospective, randomized study will include 20 patients diagnosed with COVID-19, and undergoing mechanical ventilation for the treatment of respiratory failure. Patients will be randomized in a 1:1 fashion with 10 patients (Group A) randomized to undergo core warming, and the other 10 patients (Group B) serving as the control group who will not have the ensoETM device used. Patients randomized to Group A will have core warming initiated in the ICU or other clinical environment in which they are being treated after enrollment and provision of informed consent from appropriate surrogate or legally authorized representative.","detailedDescription":"Participants will be randomized in a 1:1 fashion to core warming with the study device (ensoETM) or to standard of care (standard temperature management and treatment). The device will be used as indicated (for warming). Patient temperature measurement will be collected for both the core warming and standard of care arms during the study period (72 hours).\n\nCore warming will be performed using standard technique per instructions for use for the esophageal heat transfer device. The esophageal heat transfer device will be set to 42C temperature after initial placement, and maintained at 42C for the duration of treatment. It is expected that patient temperature will increase from baseline by 1C to 2C, but due to ongoing heat loss from the patient, the expected maximum patient temperature is below 39C. The time course of illness of COVID-19 is such that most patients no longer have fever by the time of mechanical ventilation. If patient temperature increases above this range and reaches 39.8C, the device will be set to an operating temperature of 40C, thereby preventing any further increase in patient temperature (ambient heat loss precludes patient from reaching device operating temperature).\n\nControl group patients will be managed as per standard of care currently utilized in the ICU, which will include the use of other methods of temperature management as warranted. This would include warming with a forced air blanket only in hypothermic patients (core temperature \\< 36C) or antipyretic therapy for febrile patients, as requested by the treating physician. Episodes of hypothermia are infrequent and transient in this population, and the current standard of care generally utilizes a permissive approach to fever (allowing patients to remain mildly febrile) which will continue in the control group without modification (no intentional elevation of temperature will be provided in the control group).\n\nFollow up data will be collected at 1 month following enrollment."},"conditionsModule":{"conditions":["COVID 19"],"keywords":["COVID 19","Warming","Mechanical ventilation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Randomized, single center pilot study","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","maskingDescription":"Due to the nature of this study, the physicians will not be blinded to the randomization assignment, however participants will be blinded. Once a subject is randomized, the research team will receive the randomization assignment (core warming or standard of care) and proceed with the procedures per the assignment.","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group A - core warming","type":"EXPERIMENTAL","description":"Patients randomized to Group A will have core warming with the ensoETM device initiated in the ICU or other clinical environment in which they are being treated. The device will be used as indicated (for warming). Patient temperature measurement will be collected for both the core warming and standard of care arms during the study period (72 hours).","interventionNames":["Device: ensoETM device"]},{"label":"Group B - Control Group","type":"NO_INTERVENTION","description":"Group B is serving as the control group who will not have the ensoETM device used.Control group patients will be managed as per standard of care currently utilized in the ICU, which will include the use of other methods of temperature management as warranted. This would include warming with a forced air blanket only in hypothermic patients (core temperature \\< 36C) or antipyretic therapy for febrile patients, as requested by the treating physician."}],"interventions":[{"type":"DEVICE","name":"ensoETM device","description":"Core warming will be performed using standard technique per instructions for use for the esophageal heat transfer device. The esophageal heat transfer device will be set to 42C temperature after initial placement, and maintained at 42C for the duration of treatment. It is expected that patient temperature will increase from baseline by 1C to 2C, but due to ongoing heat loss from the patient, the expected maximum patient temperature is below 39C. The time course of illness of COVID-19 is such that most patients no longer have fever by the time of mechanical ventilation.\\[41\\] If patient temperature increases above this range and reaches 39.8C, the device will be set to an operating temperature of 40C, thereby preventing any further increase in patient temperature (ambient heat loss precludes patient from reaching device operating temperature).","armGroupLabels":["Group A - core warming"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Viral load measured in tracheal aspirate 72 hours after initiation of core warming","description":"This endpoint will be compared between patients receiving core warming and those randomized to undergo standard care (standard temperature management, with or without antipyretics as needed) in order to determine an initial estimate of effect size and provide data from which to design adequately powered investigation and apply appropriate statistical testing.","timeFrame":"72 hours"}],"secondaryOutcomes":[{"measure":"PaO2/FiO2 ratio 72 hours after initiation of core warming","timeFrame":"72 hours"},{"measure":"Duration of mechanical ventilation","timeFrame":"30 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients above the age of 18 years old.\n2. Patients with a diagnosis of COVID-19 on mechanical ventilation.\n3. Patient maximum baseline temperature (within previous 12 hours) \\< 38.3C.\n4. Patients must have a surrogate or legally authorized representative able to understand and critically review the informed consent form.\n\nExclusion Criteria:\n\n1. Patients without surrogate or legally authorized representative able to provide informed consent.\n2. Patients with contraindication to core warming using an esophageal core warming device.\n3. Patients known to be pregnant.\n4. Patients with \\<40 kg of body mass.\n5. Patients with DNR status.\n6. Patients with acute stroke, post-cardiac arrest, or multiple sclerosis.\n7. Patients with history of esophageal disease\n8. Patients with a baseline epinephrine dose greater than 0.6 mcg/kg/min\n9. Patients with atrial fibrillation, atrial flutter, or other multifocal atrial tachycardia with a heart rate greater than 110 beats per minute.\n10. Patients on 0.2 mcg/kg/min or more of norepinephrine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Anne Drewry, MD","affiliation":"Washington Univeristy School of Medicine","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Barnes-Jewish Hospital","city":"Saint Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}}]},"referencesModule":{"references":[{"pmid":"33259540","type":"DERIVED","citation":"Bonfanti N, Gundert E, Drewry AM, Goff K, Bedimo R, Kulstad E. Core warming of coronavirus disease 2019 (COVID-19) patients undergoing mechanical ventilation-A protocol for a randomized controlled pilot study. PLoS One. 2020 Dec 1;15(12):e0243190. doi: 10.1371/journal.pone.0243190. eCollection 2020."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D000086382","term":"COVID-19"}],"ancestors":[{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018352","term":"Coronavirus Infections"},{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}],"browseLeaves":[{"id":"M2561","name":"COVID-19","asFound":"COVID-19","relevance":"HIGH"},{"id":"M13904","name":"Pneumonia","relevance":"LOW"},{"id":"M13914","name":"Pneumonia, Viral","relevance":"LOW"},{"id":"M10283","name":"Infections","relevance":"LOW"},{"id":"M6368","name":"Communicable Diseases","relevance":"LOW"},{"id":"M14978","name":"Respiratory Tract Infections","relevance":"LOW"},{"id":"M17522","name":"Virus Diseases","relevance":"LOW"},{"id":"M20490","name":"Coronavirus Infections","relevance":"LOW"},{"id":"M6555","name":"Coronaviridae Infections","relevance":"LOW"},{"id":"M23685","name":"Nidovirales Infections","relevance":"LOW"},{"id":"M15149","name":"RNA Virus Infections","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC01","name":"Infections"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M29176","name":"Antipyretics","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT04573062","orgStudyIdInfo":{"id":"10000089"},"secondaryIdInfos":[{"id":"000089-N"}],"organization":{"fullName":"National Institutes of Health Clinical Center (CC)","class":"NIH"},"briefTitle":"Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health","officialTitle":"Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health"},"statusModule":{"statusVerifiedDate":"2025-03-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-01-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-10-01","studyFirstSubmitQcDate":"2020-10-01","studyFirstPostDateStruct":{"date":"2020-10-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-03-07","lastUpdatePostDateStruct":{"date":"2025-03-10","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"National Institute of Neurological Disorders and Stroke (NINDS)","class":"NIH"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Background:\n\nPeople who get COVID-19 have a wide range of symptoms. They also recover from COVID-19 in different ways. In this study, researchers will use survey data to describe the different ways people experience and recover from COVID-19. They will also use the data to help create future studies to understand why some people do not fully recover.\n\nObjective:\n\nTo learn more about the range and timing of symptoms that people have before, during, and after COVID-19 infection.\n\nEligibility:\n\nPeople ages 18 and older who can give documentation of a positive COVID-19 or antibody test.\n\nDesign:\n\nParticipants will be screened with a telephone interview. It will take 15 minutes. They will provide their COVID-19 test results and medical records.\n\nParticipants will complete a second telephone interview. It will take 30 60 minutes. They will also take online surveys every 3 months for 3 years.\n\nThe interview and surveys will ask participants about their health before they got COVID-19, what happened while they had COVID-19, and what their recovery has been like.\n\nParticipants will get log-in data to take the online surveys. Completing all of the surveys the first time may take up to 3 hours. Follow-up surveys will take up to 30 minutes. Participants do not have to complete the surveys in one sitting. They will be able to save their progress and finish the surveys later.\n\nParticipants may be contacted to take part in other research studies.","detailedDescription":"Study Description:\n\nIn late 2019, the novel coronavirus SARS/CoV2 appeared in Wuhan, China. The various ways that humans will recover from COVID-19 is just starting to be observed and it is clear there will be a wide range of convalescent experiences. A year into the pandemic, the post-acute sequelae of SARS/CoV2 infection (PASC) is known to be common and includes a broad range of symptoms and potential pathologies. This phased protocol is designed to observe and study the convalescence and recoveries from acute SARS/CoV2 infections.\n\nPhase A Phase A Surveying (Phase A) will enable people in the community that are convalescing from COVID-19 to be studied using telephone interviews and internet-based questionnaires. The objective of Phase A Surveying is to observe and describe the range of medical syndromes that occur in the wake of an acute SARS/CoV2 infection.\n\nParticipants are required to be within the first five years of their recovery and have documentation of a positive laboratory test for COVID-19. Additional cohorts of persons with neurological sequelae, persons with a clinical diagnosis of COVID-19 with negative testing, persons with adverse complications after COVID 19 vaccination and participants co-enrolled in other research studies within the Division of Intramural Research will also be studied. The data collected during Phase A will describe the range of symptoms and patterns of symptom clustering of PASC. This data will also characterize the patient populations which have been or will be evaluated at the NIH Clinical Center in more detail.\n\nPhase B Evaluation (Phase B) will allow surveyed participants of research interest from Phase A to be invited to the NIH Clinical Center for a medical evaluation and to undergo a panel of standard research measurements. Each participant will be medically and psychologically characterized to best understand if their complaints can be attributed to known disorders. The observations made during Phase B will provide insights into the range, character, and subtypes of PASC. Individuals found to have disorders being studied within the Division of Intermural Research at NIH will be appropriately referred.\n\nEvaluated individuals with persistent symptoms in the absence of other demonstrable medical disease and individuals who fully recovered from a confirmed SARS/CoV2 infection will be invited back to the NIH Clinical Center for broad and deep research measurements.\n\nPhase C Deep Phenotyping (Phase C) will be synchronized with other NIH-approved deep phenotyping protocols to foster cross-phenotype comparison research with other medical syndromes, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Gulf War Illness (GWI). Deep phenotyping characterizations would be used to generate scientific hypotheses for testing in future studies and for cross-comparisons with other fatiguing disorders.\n\nPrevious epidemics have created unique medical syndromes in the past. Data from this protocol may be used to characterize PASC and any Post-COVID 19 Syndrome subtypes that may be discovered. If warranted, a Criteria Development phase will develop data-driven research consensus criteria for defining PASC and any Post-COVID 19 Syndromes.\n\nThe results of this protocol will provide novel insights into COVID-19 convalescence and its potential outcomes.\n\nThis current version of the protocol provides the details for Phase A, Phase B, and Phase C. Additional phases will be detailed in planned protocol amendments.\n\nObjectives:\n\nPrimary Objective:\n\nPhase A: To observe and describe the range of medical syndromes that occur in the wake of acute SARS/CoV2 infection.\n\nPhase B: To describe and medically characterize patients with PASC and those who fully recovered from SARS/CoV2 infection.\n\nPhase C: To compare the clinical and biological phenotypes between persons with unexplained PASC and those who fully recovered from SARS/CoV2 infection.\n\nSecondary Objectives:\n\nPhase A:\n\n* To observe and describe recovery trajectories following an acute SARS/CoV2 infection.\n* To observe and describe the range of medical syndromes and recovery trajectories of participants who report adverse effects after COVID-19 vaccination\n* To compare the range of medical syndromes and recovery trajectories of participants with a confirmed SARS/CoV2 infection to other cohorts, such as participants who have a medically confirmed diagnosis of COVID-19 without laboratory confirmation and participants who report adverse complications after COVID-19 vaccination.\n\nPhase B:\n\n* To determine the relations between acute SARS/CoV2 severity, subjective functional impairment, and objective functional performance.\n* To explore the pathophysiology of PASC and its subtypes.\n\nPhase C:\n\n* To compare the clinical and biological phenotypes between persons with PASC to historic data and samples collected on persons with post-infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, and veterans with Gulf War Illness.\n* To explore the pathophysiology of fatigue and post-exertional malaise in PASC. Fatigue will be explored using tasks designed to create muscular and cognitive fatigue. Post-exertional malaise will be explored using an exercise stress test and measuring the symptomatic and biological changes.\n\nEndpoints:\n\nOutcome measures\n\nPhase A: The number and severity of persistent symptoms associated with COVID-19 convalescence. Collected data will be used to characterize different narratives of COVID-19 convalescence.\n\nPhase B: Collected data and samples for use to perform exploratory analyses for the generation of new hypotheses regarding PASC.\n\nPhase C: Identification of hypothetical mechanisms of PASC using collected data and samples. The types of analyses to be performed will be wide ranging. Planned exploratory areas of focus may include:\n\n1. Immune system and inflammatory signaling characterization in at baseline and following maximal exercise exertion using flow cytometry, RNA sequencing, multiplex immunochemical analysis, NK cell functional analysis.\n2. Microbiome characterization at baseline and following maximal exercise exertion using shotgun metagenomics.\n3. Bioenergetics, autonomic, and metabolic characterization using mitochondrial plasmid genotyping, pulmonary spirometry, gas exchange measurements during exercise, metabolic chamber measurements of total body energy use, metabolomic analysis of stool, mitochondrion proteomics and metabolomics from muscle, and functional respiration of PBMCs using extracellular flux mito stress assay.\n4. Characterization of physical and cognitive fatigue using functional magnetic resonance imaging and transcranial magnetic stimulation at baseline and following maximal exercise exertion.\n5. Characterization of neurocognition at baseline and following maximal exercise exertion."},"conditionsModule":{"conditions":["Post-Coronavirus Disease 19"],"keywords":["Post-COVID-19","Convalescence","COVID-19","COVID","PASC","Natural History"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":1590,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Post COVID patients","description":"Individuals whom have previously had COVID -19 infection."}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Screening Phase","description":"The number and severity of persistent symptoms associated with COVID-19 convalescence. Collected data will be used to characterize different narratives of COVID-19 convalescence.","timeFrame":"End of Study"},{"measure":"Phase C: Deep Phenotyping","description":"Phase C: Immune system and inflammatory signaling characterization in at baseline and following maximal exercise exertion using flow cytometry, RNA sequencing, multiplex immunochemical analysis, NK cell functional analysis. Microbiome characterization at baseline and following maximal exercise exertion using shotgun metagenomics. Bioenergetics, autonomic, and metabolic characterization using mitochondrial plasmid genotyping, pulmonary spirometry, gas exchange measurements during exercise, metabolic chamber measurements of total body energy use, metabolomic analysis of stool, mitochondrion proteomics and metabolomics from muscle, and functional respiration of PBMCs using extracellular flux mito stress assay.","timeFrame":"End of Study"},{"measure":"Phase B: Evaluation","description":"Phase B: Standard clinical and research evaluations will be used to measure cardiopulmonary, neurological, and functional status and identify individuals with unknown PASC.","timeFrame":"End of Study"}]},"eligibilityModule":{"eligibilityCriteria":"* INCLUSION CRITERIA:\n\nFor Phase A Surveying:\n\n1590 persons who are recovering or have recovered from an acute SARS/CoV2 infection will participate.\n\nInclusion criteria for Phase A:\n\nPost-COVID-19 Convalescence (n=1190)\n\n1. Participants 18 and older\n2. Ability to provide informed consent\n3. Stated willingness to complete telephone interviews\n\n4 Reports having begun recovery from an acute SARS/CoV2 infection in the past 5 years\n\na.For participants who don t have a known recovery date, a date of 6 weeks from infection will be imposed\n\n5 Provides documentation of a positive COVID-19 Test. Approved test can include the following:\n\n1. PCR, NAA, or other EUA Approved test to confirm active COVID infection.\n2. A positive home Antigen test is acceptable when documentation of a photograph of the test with a phone-based date and time stamp is provided.\n3. A positive anti-Spike antibody test is accepted in unvaccinated individuals or those who had antibody testing prior to vaccination.\n4. A positive anti-nucleocapsid antibody test\n\n   OR\n\n   Test-Negative COVID-19 with Persistent Symptoms (n=50)\n   1. Participants 18 and older\n   2. Ability to provide informed consent\n   3. Stated willingness to complete telephone interviews\n   4. Reports having developed persistent symptoms as a consequence of an acute SARS/CoV2 infection\n   5. Provides documentation of a clinical diagnosis of an acute SARS/CoV2 infection from a medical practitioner OR meets the Clinical Criteria of the 2020 CDC Interim Case Definition for Probable SARS/CoV2 infection.\n   6. Has either negative or absent COVID-19 PCR, NAA, or other EUA Approved testing for the documented SARS/COV2 infection.\n   7. Provides documentation of a negative COVID-19 antibody test prior to vaccination.\n\n   OR\n\n   COVID-19 vaccine related medical conditions (n=50)\n   1. Participants 18 and older\n   2. Ability to provide informed consent\n   3. Stated willingness to complete telephone interviews\n   4. Reports having developed persistent symptoms as a consequence of a COVID 19 vaccination\n   5. Provides documentation of COVID-19 vaccination\n   6. Provides documentation of a COVID-19 vaccine related medical condition from a medical practitioner\n\n   OR\n\n   Participants with a history of multiple SARS-CoV-2 infections (N=100)\n   1. Participants 18 and older\n   2. Ability to provide informed consent\n   3. Stated willingness to complete telephone interviews\n   4. Reports having more than one SARS-CoV-2 infection\n   5. Provides documentation of at least one positive COVID-19 Test. Approved test can include the following:\n5. PCR, NAA, or other EUA Approved test to confirm active COVID infection.\n6. A positive home Antigen test is acceptable when documentation of a photograph of the test with a phone-based date and time stamp is provided.\n7. A positive anti-Spike antibody test is accepted in unvaccinated individuals or those who had antibody testing prior to vaccination.\n8. A positive anti-nucleocapsid antibody test\n\n   The elements of the 2020 CDC Interim Case Definition for Probable COVID-19 used for this protocol will be the Clinical Criteria:\n\n   Clinical Criteria:\n\n   At least two of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s)\n\n   OR\n\n   At least one of the following symptoms: cough, shortness of breath, or difficulty breathing\n\n   OR\n\n   Severe respiratory illness with at least one of the following:\n   * Clinical or radiographic evidence of pneumonia, OR\n   * Acute respiratory distress syndrome (ARDS).\n\n   AND\n\n   No alternative more likely diagnosis\n\n   For Phase B Evaluation:\n\n   240 persons who are recovering or have recovered from COVID-19 within the last five years will participate. The accrual ceiling is 120 PASC and 120 healthy volunteers, with a goal to identify 80 PASC participants and 80 post-COVID fully recovered healthy volunteers who may be eligible for Phase C. Time since infection (i.e. within first six months, six months to one year, one year to two years, and two years to five years) will also be considered, with a goal of recruiting at least 20 PASC participants and 20 post- COVID fully recovered participants within each of these four time frames.\n\n   Inclusion Criteria for all Phase B participants:\n   1. Adult participants aged 18 years and older\n   2. Self-reported completion of at least the 7th grade of school.\n   3. Fluency in English.\n   4. Willing and able to complete all study procedures\n   5. Participant has a primary care provider at the time of enrollment.\n   6. Able to provide informed consent\n   7. Participants must be at least six weeks out since the onset of COVID-19 symptoms with no fever for at least one week.\n   8. Participants must be within five years since starting to recover from acute COVID- 19 symptoms. The date of the start of recovery can be determined by:\n\n      * The date that fever broke for the first time\n      * The date the participant recalls starting to improve\n      * If a participant is unable to report a reliable date, a date of six weeks from the onset of COVID-19 symptoms may be imputed.\n   9. Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV- 2 infection. This may include screening interviews and/or testing.\n\n   Additional Inclusion Criteria for Mild to Moderate Illness COVID-19 with severe PASC symptoms:\n   1. Licensed Independent Practitioner documentation of a stable state of general well- health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.\n   2. A self-reported illness narrative of the development of persistent PASC symptoms after recovering from a SARS-CoV-2 infection. These include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, unrefreshing sleep, neuropathic pain, mood change, and post-exertional malaise.\n   3. Laboratory documentation of a positive COVID-19 PCR, NAA, or other EUA Approved test to confirm active COVID infection at the time of the SARS-CoV-2 infection. Participants with positive home tests during Phase A will be required to have a positive anti-SARS nucleocapsid antibody test.\n   4. Meets WHO Clinical Progression Scale of 2 - 6:\n\n      * 2: Ambulatory; symptomatic, independent\n      * 3: Ambulatory; symptomatic, assistance needed\n      * 4: Hospitalized; no oxygen therapy\n      * 5: Hospitalized; oxygen by mask or nasal prongs\n      * 6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen\n   5. Functional Criteria: Substantial symptom severity as determined using SF-36v2: score of \\<=70 physical function subscale, or \\<=50 on role physical subscale, or \\<=75 on social function subscale.\n\n   OR\n\n   Additional Inclusion Criteria for Mild or Moderate Illness COVID-19 without PASC symptoms:\n   1. Licensed Independent Practitioner documentation of a stable state of general well- health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.\n   2. A self-reported illness narrative of recovery to prior health after a SARS/CoV2 infection.\n   3. Laboratory documentation of a positive COVID-19 PCR, NAA, or other EUA Approved test to confirm active COVID infection at the time of the SARS-CoV-2 infection. Participants with positive home tests during Phase A will be required to have a positive anti-SARS nucleocapsid antibody test.\n   4. Meets WHO Clinical Progression Scale of 2 - 6:\n\n      * 2: Ambulatory; symptomatic, independent\n      * 3: Ambulatory; symptomatic, assistance needed\n      * 4: Hospitalized; no oxygen therapy\n      * 5: Hospitalized; oxygen by mask or nasal prongs\n      * 6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen\n\n   Functional Criteria: No substantial symptom severity as determined using SF-36v2: score of \\>=85 physical function subscale, and \\>= 85 on role physical subscale, and \\>= 85 on social function subscale.\n\n   OR\n\n   Additional Inclusion Criteria for Mild or Moderate Illness COVID-19 with mild to moderate PASC symptoms:\n   1. Licensed Independent Practitioner documentation of a stable state of general well-health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel.\n   2. Either a self-reported illness narrative of near recovery to prior health or a narrative of the development of persistent PASC symptoms after recovering from a SARS-CoV-2 infection. These include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, unrefreshing sleep, neuropathic pain, mood change, and post-exertional malaise.\n   3. Laboratory documentation of a positive COVID-19 PCR, NAA, or other EUA Approved test to confirm active COVID infection at the time of the SARS-CoV-2 infection. Participants with positive home tests during Phase A will be required to have a positive Anti-SARS nucleocapsid antibody test.\n   4. Meets WHO Clinical Progression Scale\\[61\\] of 2 - 6:\n\n      * 2: Ambulatory; symptomatic, independent\n      * 3: Ambulatory; symptomatic, assistance needed\n      * 4: Hospitalized; no oxygen therapy\n      * 5: Hospitalized; oxygen by mask or nasal prongs\n      * 6: Hospitalized; oxygen by non-invasive ventilation or high flow oxygen\n   5. Functional Criteria: Mild to moderate symptom severity as determined using SF-36v2: score of between 71 and 84 on the physical function subscale, or between 51 and 84 on role physical subscale, or between 76 and 84 on social function subscale.\n\n   For Phase C Deep Phenotyping:\n\n   Inclusion Criteria for Mild to Moderate Illness COVID-19 with PASC symptoms:\n   1. Met inclusion and exclusion criteria for Mild to Moderate Illness COVID-19 with severe post-acute COVID-19 symptoms after completing Phase B.\n   2. No alternative explanation for PASC symptoms identified by adjudication committee during Phase B.\n   3. Fluency in English\n\n   OR\n\n   Inclusion Criteria for Mild or Moderate Illness COVID-19 without PASC symptoms:\n   1. Met inclusion and exclusion criteria for Mild to Moderate Illness COVID-19 without post-acute COVID-19 symptoms after completing Phase B.\n   2. Fluency in English\n\n   EXCLUSION CRITERIA:\n\n   Exclusion criteria for Phase A:\n   1. Not willing to provide personal identifying information to investigative team\n   2. Cognitive impairment that is severe enough to limit consent capacity\n\n   Exclusion criteria for Phase B Evaluation:\n\n   Information collected from Phase A interviews, review of medical records, and discussions with consented Phase A participants will be used to determine if a participant will be excluded from participation.\n   1. Current or past psychotic disorder including depression with psychosis, bipolar disorder with psychotic symptoms and schizophrenia\n   2. Major depression disorder, generalized anxiety disorder, post-traumatic stress disorder, panic disorder, or obsessive-compulsive disorder unless managed for more than six months with a stable treatment regimen\n   3. Current or past substance use disorder within last five years. Marijuana use within the past five years will not be an exclusion.\n   4. Positive urine toxicology screening for anything other than marijuana\n   5. Current suicidal ideation\n   6. History of head injury leading to moderate or severe traumatic brain injury. Persons having a history of mild TBI (mTBI) will not be excluded.\n   7. Women who are pregnant, breastfeeding, or are within one-year post-partum.\n   8. Current or previous malignancy. A history of malignancy that has fully resolved with surgical resection only (e.g. no chemotherapy, radiation therapy, or immunotherapy) will be allowed.\n   9. Current systemic immunologic disorders (e.g. Type 1 diabetes, rheumatoid arthritis). Local immunological disorder (e.g. atopic dermatitis, stable autoimmune thyroid disease) and allergic disorders will be allowed.\n   10. Current or previous long-term immune suppressive therapy. Recent or current steroid use for the treatment of COVID-19, PASC, recent allergic reactions, and topical steroid use is allowed.\n   11. Any premorbid medical condition that would potentially cause fatigue and exercise intolerance that would exclude from participation in Phase C. This includes many chronic medical diseases, such\n\n       as congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, severe arthritis, uncontrolled asthma, renal failure, fibromyalgia, and ME/CFS.\n   12. Active participation in a clinical protocol (e.g. anti-inflammatory drug intervention study) which includes an intervention that may affect the results of the current study.\n   13. Not willing to allow for research data and samples to be shared broadly with other researchers.\n   14. Employees at NIH that are under the direct supervision of the study investigators (family members of NIH employees are permitted to participate).\n   15. Symptom severity that makes it impossible for the volunteer to travel to NIH.\n\n   Exclusion criteria for Phase C Deep Phenotyping:\n\n   Exclusion criteria for all Phase C participants:\n   1. Current or past psychotic disorder including depression with psychosis, bipolar disorder with psychotic symptoms and schizophrenia\n   2. Current DSM-5-defined major depression disorder, generalized anxiety disorder, post-traumatic stress disorder, panic disorder, or obsessive-compulsive disorder unless managed for more than six months with a stable treatment regimen\n   3. Current or past substance use disorder within last five years as diagnosed on the Structured Clinical Interview for DSM-5 (SCID-5). Mar...","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"1590 persons within five years of convalescence of a single acute SARS-CoV-2 will participate, including at least 250 adults recovering from neurological sequelae. Additional cohorts of 50 adults with a clinical diagnosis of SARS-CoV-2 infection with negative or absent PCR testing and negative antibody testing and 50 adults with medical documentation of a COVID-19 vaccine related medical condition will be enrolled. Participants in NIH protocols 20CC0113: Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons and 000102-CC: COVID-19, Chronic Adaptation, and Response to Exercise may also co-enroll. Up to 240 Phase A participants will complete a Phase B research evaluation. Additionally, 80 unexplained PASC participants and 80 post-COVID recovered controls who completed Phase B will be invited for a Phase C deep phenotyping visit, with a target of completing measures on 50 in each group.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Angelique Gavin","role":"CONTACT","phone":"(301) 402-0880","email":"angelique.gavin@nih.gov"},{"name":"Brian T Walitt, M.D.","role":"CONTACT","phone":"(301) 496-5043","email":"brian.walitt@nih.gov"}],"overallOfficials":[{"name":"Brian T Walitt, M.D.","affiliation":"National Institute of Neurological Disorders and Stroke (NINDS)","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"National Institutes of Health Clinical Center","status":"RECRUITING","city":"Bethesda","state":"Maryland","zip":"20892","country":"United States","contacts":[{"name":"For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)","role":"CONTACT","phone":"800-411-1222","phoneExt":"TTY8664111010","email":"prpl@cc.nih.gov"}],"geoPoint":{"lat":38.98067,"lon":-77.10026}}]},"referencesModule":{"references":[{"pmid":"32287140","type":"BACKGROUND","citation":"Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-773. doi: 10.14309/ajg.0000000000000620."},{"pmid":"32167524","type":"BACKGROUND","citation":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994. Erratum In: JAMA Intern Med. 2020 Jul 1;180(7):1031. doi: 10.1001/jamainternmed.2020.1429."},{"pmid":"32220203","type":"BACKGROUND","citation":"Chen ATC, Coura-Filho GB, Rehder MHH. Clinical Characteristics of Covid-19 in China. N Engl J Med. 2020 May 7;382(19):1860. doi: 10.1056/NEJMc2005203. Epub 2020 Mar 27. No abstract available."}],"seeAlsoLinks":[{"label":"NIH Clinical Center Detailed Web Page","url":"https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_000089-N.html"}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D018352","term":"Coronavirus Infections"},{"id":"D000086382","term":"COVID-19"},{"id":"D003289","term":"Convalescence"}],"ancestors":[{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"},{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M2561","name":"COVID-19","asFound":"Coronavirus Disease 19","relevance":"HIGH"},{"id":"M20490","name":"Coronavirus Infections","asFound":"Coronavirus","relevance":"HIGH"},{"id":"M6513","name":"Convalescence","asFound":"Convalescence","relevance":"HIGH"},{"id":"M10283","name":"Infections","relevance":"LOW"},{"id":"M6368","name":"Communicable Diseases","relevance":"LOW"},{"id":"M6555","name":"Coronaviridae Infections","relevance":"LOW"},{"id":"M23685","name":"Nidovirales Infections","relevance":"LOW"},{"id":"M17522","name":"Virus Diseases","relevance":"LOW"},{"id":"M15149","name":"RNA Virus Infections","relevance":"LOW"},{"id":"M13904","name":"Pneumonia","relevance":"LOW"},{"id":"M13914","name":"Pneumonia, Viral","relevance":"LOW"},{"id":"M14978","name":"Respiratory Tract Infections","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"M22700","name":"Disease Attributes","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC01","name":"Infections"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06761612","orgStudyIdInfo":{"id":"RRPV-24-02-Retail-009"},"organization":{"fullName":"Biomedical Advanced Research and Development Authority","class":"FED"},"briefTitle":"Retail COVID-19 Study","officialTitle":"A Longitudinal Assessment of Serology and Effectiveness to Determine COVID-19 Vaccine Correlates of Risk (CoR) and Correlates of Protection (CoP) in a Heterogeneous US Population Through Use of Decentralized Sites and Approaches for Data/specimen Collection"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-10-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-02","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-12-05","studyFirstSubmitQcDate":"2024-12-31","studyFirstPostDateStruct":{"date":"2025-01-07","type":"ESTIMATED"},"lastUpdateSubmitDate":"2025-01-07","lastUpdatePostDateStruct":{"date":"2025-01-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Biomedical Advanced Research and Development Authority","class":"FED"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection. Additionally, the operational capability of retail pharmacy infrastructure to collect longitudinal data and biological samples needs to be assessed. This study aims to fill these gaps by determining correlates of protection (CoP), assessing the infrastructure's capability, and examining demographic and geographic differences in participation.","detailedDescription":"This multi-center study will utilize a prospective, longitudinal observational design to assess CoR and CoP for COVID-19 vaccinations. Prior to enrollment in this study, participants will receive a federally licensed and authorized vaccine, manufactured by Pfizer-BioNTech or Moderna, for the prevention of COVID-19. Each participant will complete a pre-screener questionnaire which will collect information to confirm the participant's eligibility. Upon passing the pre-screener, the participant will complete their electronic consent form and will be enrolled in the study within 48 hours of their vaccination with blood collected to establish baseline for humoral immune marker. A subset of total enrollment, a cohort of 80 participants, will also enroll in the PBMC cohort; participants in the PBMC cohort will enroll in the study within 24 hours of their vaccination with blood collected to establish baseline immune marker levels.\n\nDuring this study, participants will complete five (5) visits on site (Day 01, Day 31, Day 91, Day 181, Day 366), which will involve data collection and a blood draw. Participants enrolled in the PBMC cohort will have an additional blood draw at Day 01, Day 31, Day 181, and Day 366.\n\nAll study participants will complete a weekly electronic patient reported outcome (ePRO) to report symptoms of COVID-19, and to report if they have been exposed to anyone who has tested positive for COVID-19.\n\nParticipants will be asked to report to the clinic for an Abbott ID NOW nasal swab test (via molecular assay) when: participant has at least one symptom with or without a fever, and/or if the participant has recent exposure or close contact to another person with COVID-19.\n\nThis study aims to enroll at least 90 COVID-19 endpoint cases, based on an annual incidence rate of 2.5%."},"conditionsModule":{"conditions":["COVID - 19"],"keywords":["Covid-19","Vaccines","Correlates of Protective Immunity"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"1 Year","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":3600,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Primary Cohort","description":"Cohort Provides blood draws during on-study visits","interventionNames":["Biological: FDA approved mRNA vaccines"]},{"label":"PBMC Cohort","description":"Up to 80 participants providing PBMCs","interventionNames":["Biological: FDA approved mRNA vaccines"]}],"interventions":[{"type":"BIOLOGICAL","name":"FDA approved mRNA vaccines","description":"This study is non-interventional as participants will have received an FDA approved mRNA COVID-19 vaccine prior to entering the study. The study protocol does not determine or allocate receipt of vaccine","armGroupLabels":["PBMC Cohort","Primary Cohort"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Serum S protein-specific binding antibody (bAb) concentrations (peak and exposure proximal assessments) Serum SARS-CoV-2 specific neutralizing antibody (nAb) titers (peak and exposure proximal assessments);","description":"Correlates of Protective Immunity","timeFrame":"Day 1, Day 31, Day 91, Day 181, and Day 366 (i.e., visits 1-5)"},{"measure":"Valid Viable specimens for SARS-CoV-2 testing","description":"Number of viable specimens collected at retail pharmacies or retail clinics over the Day 366 follow-up period that meet quality standards required for laboratory analysis.","timeFrame":"Day 1, Day 31, Day 91, Day 181, and Day 366 (i.e., visits 1-5)."},{"measure":"Number of viable specimens for laboratory analysis","description":"Viable specimens collected at retail pharmacies or retail clinics that meet quality standards required for laboratory analysis.","timeFrame":"Day 1, Day 31, Day 91, Day 181, and Day 366 (i.e., visits 1-5)"},{"measure":"Number of valid specimens for CoP testing","description":"Valid specimens collected at retail pharmacies or retail clinics that meet quality standards required for CoP testing.","timeFrame":"Day 1, Day 31, Day 91, Day 181, and Day 366 (i.e., visits 1-5)"}],"secondaryOutcomes":[{"measure":"Representativeness of number of self-collected nasal swabs and blood specimens","description":"Number of self-collected nasal swabs and blood specimens received over the Day 366 follow-up period overall and stratified by participant demographic and social determinants of health.","timeFrame":"Day 1, Day 31, Day 91, Day 181, and Day 366 (i.e., visits 1-5). Various"},{"measure":"Representativeness of Number of valid COVID-19 tests","description":"COVID-19 resulting in a positive or negative result for SARS-CoV-2 infection overall and stratified by participant demographic and social determinants of health.","timeFrame":"Day 1, Day 31, Day 91, Day 181, and Day 366 (i.e., visits 1-5)"},{"measure":"Assessment of participant recruitment speed","description":"Participant recruitment speed measured as time of vaccination to time of enrollment, overall and by site, as well as time to full enrollment overall and stratified by age.","timeFrame":"Day 1, Day 31, Day 91, Day 181, and Day 366 (i.e., visits 1-5)"},{"measure":"Assessment of participant retention","description":"Participant retention over study period (from Day 1 through Day 366 follow-up) overall and stratified by age.","timeFrame":"Day 1, Day 31, Day 91, Day 181, and Day 366 (i.e., visits 1-5)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. People 3 years of age at time of enrollment.\n2. Willing and able to provide informed consent, or assent in pediatric population, if appropriate, prior to initiation of study procedures.\n3. Able to understand and comply with planned study procedures.\n4. Available for all study data collection points.\n5. Receipt of the most recent FDA-licensed and authorized COVID-19 vaccine (i.e., the 2024-2025 Moderna COVID-19 vaccine or the 2024-2025 Pfizer-BioNTech COVID-19 vaccine which includes the KP.2 strain of the JN.1-lineage vaccine), as recommended by the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) and outlined in the FDA's updated guidance, administered within 48 hours of enrollment.\n\nPBMC cohort only:\n\nPeople ages 18 years at time of enrollment. Available for first blood sample collection within 24 hours of vaccine.\n\nExclusion Criteria:\n\n1. Currently participating or plans to participate in another clinical trial involving an investigational product before completing this study.\n2. Planned to receive another COVID-19 vaccine within 180 days.\n3. Receipt of COVID-19 vaccination within 90 days prior to current vaccination.\n4. Planned receipt of Shingrix vaccine within 28 days after receipt of COVID-19 vaccination.\n5. Self-report of recently confirmed COVID-19 infection within 30 days.\n6. Any disease or medical condition that, in the opinion of the principal investigator or sub-investigator, is a contraindication to study participation.\n\nPBMC cohort only:\n\nConfirmed positive urine pregnancy test at study visits per Schedule of Activities.","healthyVolunteers":true,"sex":"ALL","minimumAge":"3 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"],"studyPopulation":"Prior to enrollment in this study, participants will receive a federally licensed and authorized vaccine, manufactured by Pfizer-BioNTech or Moderna, for the prevention of COVID-19. Each participant will complete a pre-screener questionnaire which will collect information to confirm the participant's eligibility. Upon passing the pre-screener, the participant will complete their electronic consent form and will be enrolled in the study within 48 hours of their vaccination with blood collected to establish baseline for humoral immune marker. A subset of total enrollment, a cohort of 80 participants, will also enroll in the PBMC cohort; participants in the PBMC cohort will enroll in the study within 24 hours of their vaccination with blood collected to establish baseline immune marker levels.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Sara Jaffer","role":"CONTACT","phone":"800-371-5450","email":"sara.jaffer@walgreens.com"}],"locations":[{"facility":"Walgreens - 3298 S John Young Pkwy","status":"RECRUITING","city":"Kissimmee","state":"Florida","zip":"34746","country":"United States","geoPoint":{"lat":28.30468,"lon":-81.41667}},{"facility":"Walgreens - 1554 E 55th St","status":"RECRUITING","city":"Chicago","state":"Illinois","zip":"60615","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Walgreens - 4385 S Archer Ave","status":"RECRUITING","city":"Chicago","state":"Illinois","zip":"60632","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Walgreens - 811 Madison St","status":"RECRUITING","city":"Oak Park","state":"Illinois","zip":"60302","country":"United States","geoPoint":{"lat":41.88503,"lon":-87.7845}},{"facility":"Walgreens - 7251 Lake St","status":"RECRUITING","city":"River Forest","state":"Illinois","zip":"60305","country":"United States","geoPoint":{"lat":41.89781,"lon":-87.81395}},{"facility":"Walgreens - 15100 W 87th Street Pkwy","status":"RECRUITING","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Walgreens - 7500 Metcalf Ave","status":"RECRUITING","city":"Overland Park","state":"Kansas","zip":"66204","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"Walgreens - 215 Beach St","status":"RECRUITING","city":"Malden","state":"Massachusetts","zip":"02148","country":"United States","geoPoint":{"lat":42.4251,"lon":-71.06616}},{"facility":"Walgreens - 17811 E US Highway 24","status":"RECRUITING","city":"Independence","state":"Missouri","zip":"64056","country":"United States","geoPoint":{"lat":39.09112,"lon":-94.41551}},{"facility":"Walgreens - 3845 Broadway Blvd","status":"RECRUITING","city":"Kansas City","state":"Missouri","zip":"64111","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Walgreens - 2630 NE Vivion","status":"RECRUITING","city":"Kansas City","state":"Missouri","zip":"64119","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Walgreens - 6401 W Charleston Blvd","status":"RECRUITING","city":"Las Vegas","state":"Nevada","zip":"89146","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Walgreens - 1445 W Craig Rd","status":"RECRUITING","city":"North Las Vegas","state":"Nevada","zip":"89032","country":"United States","geoPoint":{"lat":36.19886,"lon":-115.1175}},{"facility":"Walgreens - 3218 Atlantic Ave","status":"RECRUITING","city":"Atlantic City","state":"New Jersey","zip":"08401","country":"United States","geoPoint":{"lat":39.36428,"lon":-74.42293}},{"facility":"Walgreens - 520 Convery Blvd","status":"RECRUITING","city":"Perth Amboy","state":"New Jersey","zip":"08861","country":"United States","geoPoint":{"lat":40.50677,"lon":-74.26542}},{"facility":"Walgreens - 420 N Frazier St","status":"RECRUITING","city":"Conroe","state":"Texas","zip":"77301","country":"United States","geoPoint":{"lat":30.31188,"lon":-95.45605}},{"facility":"Walgreens - 1919 W Gray St","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77019","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Walgreens - 7440 FM 1960 Rd E","status":"RECRUITING","city":"Humble","state":"Texas","zip":"77346","country":"United States","geoPoint":{"lat":29.99883,"lon":-95.26216}},{"facility":"Walgreens - 8430 Broadway St","status":"RECRUITING","city":"Pearland","state":"Texas","zip":"77584","country":"United States","geoPoint":{"lat":29.56357,"lon":-95.28605}},{"facility":"Walgreens - 3316 Avenue H","status":"RECRUITING","city":"Rosenberg","state":"Texas","zip":"77471","country":"United States","geoPoint":{"lat":29.55718,"lon":-95.80856}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR","ANALYTIC_CODE"]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D000086382","term":"COVID-19"}],"ancestors":[{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018352","term":"Coronavirus Infections"},{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}],"browseLeaves":[{"id":"M2561","name":"COVID-19","asFound":"COVID-19","relevance":"HIGH"},{"id":"M13904","name":"Pneumonia","relevance":"LOW"},{"id":"M13914","name":"Pneumonia, Viral","relevance":"LOW"},{"id":"M10283","name":"Infections","relevance":"LOW"},{"id":"M6368","name":"Communicable Diseases","relevance":"LOW"},{"id":"M14978","name":"Respiratory Tract Infections","relevance":"LOW"},{"id":"M17522","name":"Virus Diseases","relevance":"LOW"},{"id":"M20490","name":"Coronavirus Infections","relevance":"LOW"},{"id":"M6555","name":"Coronaviridae Infections","relevance":"LOW"},{"id":"M23685","name":"Nidovirales Infections","relevance":"LOW"},{"id":"M15149","name":"RNA Virus Infections","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC01","name":"Infections"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M17360","name":"Vaccines","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06698549","orgStudyIdInfo":{"id":"ALG-097558-703 / DMID 24-0022"},"organization":{"fullName":"Aligos Therapeutics","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Renal Impairment and in Healthy Subjects with Normal Renal Function","officialTitle":"A Phase 1 Non-Randomized, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Renal Impairment and in Healthy Subjects with Normal Renal Function"},"statusModule":{"statusVerifiedDate":"2024-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-02-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-11-12","studyFirstSubmitQcDate":"2024-11-18","studyFirstPostDateStruct":{"date":"2024-11-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-02-11","lastUpdatePostDateStruct":{"date":"2025-02-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Aligos Therapeutics","class":"INDUSTRY"},"collaborators":[{"name":"National Institute of Allergy and Infectious Diseases (NIAID)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects without renal impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of renal impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses."},"conditionsModule":{"conditions":["COVID 19"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"This study is non-randomized, open-label, parallel group study. In Part 1, Cohort 1 will enroll severely renally impaired subjects and Cohort 2 will enroll subjects without renal impairment. In Part 2, if triggered, Cohort 3 will enroll mildly renally impaired subjects and Cohort 4 moderately renally impaired subjects. Cohort 5 will enroll subjects without renal impairment.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Subjects with Severe Renal Impairment","type":"EXPERIMENTAL","description":"Subjects with severe renal impairment will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \\[Q12H\\]) for 6 days for 11 total doses.","interventionNames":["Drug: ALG-097558"]},{"label":"Subjects with Normal Renal Function","type":"EXPERIMENTAL","description":"Subjects with normal renal function will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \\[Q12H\\]) for 6 days for 11 total doses.","interventionNames":["Drug: ALG-097558"]},{"label":"Subjects with Mild Renal Impairment (Optional)","type":"EXPERIMENTAL","description":"Subjects with mild renal impairment will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \\[Q12H\\]) for 6 days for 11 total doses.","interventionNames":["Drug: ALG-097558"]},{"label":"Subjects with Moderate Renal Impairment (Optional)","type":"EXPERIMENTAL","description":"Subjects with moderate renal impairment will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \\[Q12H\\]) for 6 days for 11 total doses.","interventionNames":["Drug: ALG-097558"]}],"interventions":[{"type":"DRUG","name":"ALG-097558","description":"Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)","armGroupLabels":["Subjects with Mild Renal Impairment (Optional)","Subjects with Moderate Renal Impairment (Optional)","Subjects with Normal Renal Function","Subjects with Severe Renal Impairment"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Area under the concentration time curve [AUC]","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in plasma","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"},{"measure":"Maximum plasma concentration [Cmax]","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in plasma","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"},{"measure":"Minimum plasma concentration [Cmin]","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in plasma","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"},{"measure":"C0 [predose]","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in plasma","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"},{"measure":"Half-life [t1/2]","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in plasma","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"},{"measure":"Time to maximum plasma concentration [Tmax]","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in plasma","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"},{"measure":"Apparent Clearance (CL/F)","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in plasma","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"},{"measure":"Apparent Volume of Distribution (V/F)","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in plasma","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"},{"measure":"Total Amount of Drug Excreted in Urine (Ae)","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in urine","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"},{"measure":"Renal Clearance (CLr)","description":"Pharmacokinetic parameters of ALG-097558 and metabolite ALG-097730 in urine","timeFrame":"Pre-dose (-0.75 hours) up to Day 8"}],"secondaryOutcomes":[{"measure":"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","description":"The number and severity of treatment emergent events in subjects with renal impairment and subjects with normal renal function as assessed by DAIDS v2.1 (July 2017)","timeFrame":"Up to 20 Days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for All Subjects:\n\n1. Male and Female between 18 and 75 years old\n2. Body Mass Index (BMI) 17.5 to 40.0 kg/m\\^2 and a total body weight \\>50 kg (110 lb)\n3. Female subjects must either be not of childbearing potential or if they are a woman of childbearing potential, they are only eligible if they and any non-sterile, male sexual partners agree to use highly effective contraceptive therapy\n\nInclusion Criteria for Subjects with Normal Renal Function:\n\n1. Good general health as defined by no clinically relevant abnormalities identified by Medical History and a vital signs, clinical laboratory and 12-lead electrocardiogram (ECG) assessment\n2. Subjects must fit the demographic-matching criteria including body weight, age, and to the extent possible, gender\n3. Normal renal function (estimated Glomerular Filtration Rate \\[eGFR\\] 90 mL/min) with no known or suspected renal impairment\n\nInclusion Criteria for Subjects with Impaired Renal Function:\n\n1. Subject satisfies the eGFR criteria for renal impairment classification within 28 days of study drug administration\n2. Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).\n3. Stable concomitant medications for the management of an individual subject's medical history for at least 28 days prior to screening\n4. Subjects must have a 12-lead ECG and vital signs assessment that meet the protocol criteria\n\nExclusion Criteria for All Subjects:\n\n1. Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results and interpretation\n2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or clinical evidence at screening of significant (subjects with normal renal function) or unstable (subjects with renal impairment) cardiac disease etc.\n3. Subjects with a history of clinically significant drug allergy\n4. Subjects with a recent (within 1 year of randomization) history or current evidence of drug abuse or recreational drug use\n5. Excessive use of alcohol defined as regular consumption of 14 units/ week for women and 21 units/week for men\n6. Unwilling to abstain from alcohol use for 48 hours prior to start of the study through end of study follow up\n7. Subjects with Hepatitis A, B, C, E or HIV-1/HIV-2 infection or acute infections such as SARS- CoV-2 infection\n8. Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values \\>2x upper limit of normal (ULN)\n9. Subjects with bilirubin (total, direct) \\>1.5x ULN (unless Gilbert's is suspected)\n10. Positive pregnancy test; females must not be pregnant at enrollment\n\nExclusion Criteria for Subjects with Normal Renal Function:\n\n1. Hemoglobin \\<10 g/dL\n\nExclusion Criteria for Subjects with Impaired Renal Function:\n\n1. Participants requiring hemodialysis and/or peritoneal dialysis\n2. Hemoglobin \\<9 g/dL","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Jen Rito","role":"CONTACT","phone":"(800) 466-6059","email":"info@aligos.com"}],"locations":[{"facility":"University of Miami","status":"NOT_YET_RECRUITING","city":"Miami","state":"Florida","zip":"33136","country":"United States","contacts":[{"name":"Alisa Danielyan","role":"CONTACT","email":"alice_danielyan@yahoo.com"}],"geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Orlando Clinical Research Center","status":"RECRUITING","city":"Orlando","state":"Florida","zip":"32809","country":"United States","contacts":[{"name":"Derek Bell","role":"CONTACT","email":"dbell@ocrc.net"}],"geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Genesis Clinical Trials","status":"RECRUITING","city":"Tampa","state":"Florida","zip":"33603","country":"United States","contacts":[{"name":"Derik Navarro","role":"CONTACT","email":"dnavarro@genesistrials.com"}],"geoPoint":{"lat":27.94752,"lon":-82.45843}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D051437","term":"Renal Insufficiency"}],"ancestors":[{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"}],"browseLeaves":[{"id":"M2561","name":"COVID-19","relevance":"LOW"},{"id":"M26718","name":"Renal Insufficiency","asFound":"Renal Impairment","relevance":"HIGH"},{"id":"M10698","name":"Kidney Diseases","relevance":"LOW"},{"id":"M17319","name":"Urologic Diseases","relevance":"LOW"},{"id":"M2875","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M27093","name":"Female Urogenital Diseases","relevance":"LOW"},{"id":"M14127","name":"Pregnancy Complications","relevance":"LOW"},{"id":"M8399","name":"Female Urogenital Diseases and Pregnancy Complications","relevance":"LOW"},{"id":"M27095","name":"Male Urogenital Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC01","name":"Infections"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT04790240","orgStudyIdInfo":{"id":"CHM2282395-1"},"organization":{"fullName":"All Natural Medicine Clinic, LLC","class":"OTHER"},"briefTitle":"Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)","officialTitle":"The Trial Uses Medicinal Herbs to Direct T Cells to Engulf the COVID-19 Virus and Protect the Organs Well","acronym":"COVID"},"statusModule":{"statusVerifiedDate":"2025-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-01-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-05-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-02-23","studyFirstSubmitQcDate":"2021-03-09","studyFirstPostDateStruct":{"date":"2021-03-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-02-16","lastUpdatePostDateStruct":{"date":"2025-02-19","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Wanzhu Hou","investigatorTitle":"President","investigatorAffiliation":"All Natural Medicine Clinic, LLC"},"leadSponsor":{"name":"All Natural Medicine Clinic, LLC","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning. Once compromised by inflammation, the immune system loses its capacity to recognize antigens and dependably defend the body against disease and illness.\n\nWhen COVID-19 invades humans, it causes an immune-storm (cytokine-storm) that can directly damage the organ(s), leading to death. The virus is an antigen - a trigger - but it is not the actual reason that causes organ failure and death; instead, it is the body's over immune reaction that is the cause. In attempting to protect the body, the immune system overreacts to the antigen, which includes the infected cells, which causes a cytokine-storm, and the subsequent and rapid shut down of the infected individual's organ(s)' structure, leaving the body without sufficient strength or time to fight back. When the medical herbs join the body, it can slow down the immune reaction. Medical herbs benefit the physical body; they protect the cells and organism structure and mediate the immune response, allowing the T cells to kill the virus (mutated or not) internally. Such success has been achieved by the All Natural Medicine Clinic during pre-clinical trials.\n\nThis clinical study's goal is to demonstrate that the immune system can be rebuilt and retrained, using natural medicine (i.e., medical herbs), to kill the virus without causing the immune storm, and to explore the mechanism by which these medical herbs, which have been used for thousands of years for healing, achieve results.","detailedDescription":"According to CDC data, as of January 30, 2021, 25,780,144 individuals residing in the United States had been infected by COVID-19 and 435,151 had died as a result of the disease. No drug has yet been identified that explicitly kills the COVID-19 virus. While various vaccines have been developed to prevent infection, the virus continues to mutate, and scientific research remains behind the virus trajectory.\n\nThe human immune system, when functioning properly, can prevent the body from succumbing to infections from external sources and from internal cell mutations, including the COVID-19 virus and cancer cells. That is, the defense system comes from nature. This clinical study proves that the immune system can respond to those antigens and kill them if the immune system is given a chance. However, the human immune system can become compromised through inflammation and subsequently unable to successfully prevent infection and cancer.\n\nWhen COVID-19 invades humans, it causes an immune-storm (cytokine-storm) that can directly damage the organ(s), leading to death. The virus is an antigen - a trigger - but it is not the actual reason that causes organ failure and death; instead, it is the body's over-immune reaction that is the cause. In attempting to protect the body, the immune system overreacts to the antigen, which includes the infected cells, which causes a cytokine-storm, and the subsequent and rapid shut down of the infected individual's organ(s)' structure, leaving the body without sufficient strength or time to fight back.\n\nMedical herbs can mediate the immunity disorder caused by infections, and mutated cells, including COVID-19 and its mutations. Our pre-clinical study found that the medical herbs inhibit the inflammation expression, reduce the chance of cytokine-storm, prevent deterioration, and reduce the mortality rate. In addition, the T cells can perform their job when the inflammation is under control. The virus and cancer cells belong to antigens that should be killed by natural killer (NK) cells and T cells. This clinical study aims not to provide drugs to kill the antigens, but rather to create the necessary conditions inside the human body to allow the immune system a chance to overcome the antigens. The clinic has used this treatment concept to successfully treat infected patients and cancer patients."},"conditionsModule":{"conditions":["Covid19 Virus Infection"],"keywords":["Medicinal Herbs","Virus","COVID-19","Coronavirus Disease 2019","Infections","Inflammation","Immunity","Metabolite","clots","thrombus","Viral Pneumonia","Fever","Cough","Chest congestion"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"The participants are randomly divided into two groups: the treatment group and the control group. Both groups receive the same medications, but the treatment group also receives medical herbs to compare both groups' differences on their symptoms and blood data, virus marks.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","maskingDescription":"The participants will be randomly divided into two groups by computer. The conventional practitioners who prescribe medications for the participants will not know who will go to the treatment group. Participants will know which group they are in.","whoMasked":["PARTICIPANT","CARE_PROVIDER"]}},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Inflammation (I)","type":"ACTIVE_COMPARATOR","description":"1. Upper respiratory inflammation.\n2. Fever.\n3. Lower respiration inflammation.","interventionNames":["Dietary Supplement: Inflammation (I)","Drug: Standard of care"]},{"label":"Inflammation (II)","type":"ACTIVE_COMPARATOR","description":"Cough, chest pain","interventionNames":["Dietary Supplement: Inflammation (II)","Drug: Standard of care"]},{"label":"Inflammation (III)","type":"ACTIVE_COMPARATOR","description":"1. Metabolites\n2. Clots","interventionNames":["Dietary Supplement: Inflammation (III)","Drug: Standard of care"]}],"interventions":[{"type":"DIETARY_SUPPLEMENT","name":"Inflammation (I)","description":"1. upper respiratory inflammation (PurInf (I)): Lonicerae Flos 2.4g, Forsythiae Fructus 2.4g, Schizonepetae Herba 2g, Saposhnikoviae Radix 2g, Cicadae Periostracum 1g, Sophorae flavescentis Radix 2.4g, Atractylodis Rhizoma 2g, Angelicae dahuricae Radix 2g, Menthae haplocalycis Herba 2g, Arctii Fructus 2g, Glycyrrhizae Radix 1g\n2. high fever (PurInf (II)): Bupleuri Radix 3g, Scutellariae Radix 2.4g, Gypsum fibrosum 4g, Anemarrhenae Rhizoma 3g\n3. lower Respiratory system inflammation (PurInf (III)): Scutellariae Radix 2.4g, Coptidis Rhizoma 1g, Phellodendri Cortex 2.4g, Gardeniae Fructus 2.4g, Houttuyniae Herba 4g, Golden Buckwheat 3g","armGroupLabels":["Inflammation (I)"],"otherNames":["PurInf (I), PurInf (II), PurInf(III)"]},{"type":"DIETARY_SUPPLEMENT","name":"Inflammation (II)","description":"Platycodi Radix 2.4g, Peucedani Radix 2.4g, Cynanchi stauntonii Rhizoma 2.4g, Asteris Radix 2.4g, Stemonae Radix 2.4g, Lepidii Descurainiae Semen 2.4g, Plantaginis Semen 2.4g","armGroupLabels":["Inflammation (II)"],"otherNames":["PurCo"]},{"type":"DIETARY_SUPPLEMENT","name":"Inflammation (III)","description":"1. Metabolites, abnormal fluids (PurPhl):\n\n   Citri reticulatae Pericarpium 1.2g, Citri grandis Exocartium rubrum 2g, Aurantii Fructus immaturu 2g, Pinelliae Rhizoma preparatum 2.4g, Arisaematis Rhizoma preparatum 2.4g, Amoni Fructus 1g, Trichosanthis Fructus 2.4g, Fritillatiae cirrhosae Bulbu 2.4g, Poria 2.4g, Rhei Radix et Rhizoma 1g\n2. Capillaries circulation disorder (PurClo):\n\nSalviae miltiorrhizae Radix 2.4g, Curcumae Radix 2.4g, Paeoniae Radix rubra 2.4g, Persicae Semen 2.4g, Carthami Flos 2.4g","armGroupLabels":["Inflammation (III)"],"otherNames":["PurPhl, PurClo"]},{"type":"DRUG","name":"Standard of care","description":"remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \\& Imdevimab.","armGroupLabels":["Inflammation (I)","Inflammation (II)","Inflammation (III)"],"otherNames":["Medications"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"recovering damaged organ","description":"comparing imagen of lungs","timeFrame":"3 weeks"},{"measure":"inhibiting inflammation","description":"comparing C-reactive protein (CRP)","timeFrame":"3 weeks"},{"measure":"preventing the antibody depositing on antigen","description":"measuring complement: C3, C4","timeFrame":"6 weeks"}],"secondaryOutcomes":[{"measure":"monitoring the antibody level","description":"measuring immunoglobulin M (IgM), immunoglobulin G (IgG)","timeFrame":"6 weeks"},{"measure":"correcting reversed immunity ratio","description":"measuring cluster of differentiation 4/cluster of differentiation 8 (CD4/CD8)","timeFrame":"6 weeks"},{"measure":"tracking the COVID virus marks","description":"SARS-CoV-2 Diagnostic (Molecular or Antigen) Testing","timeFrame":"3 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nA subject will be eligible for inclusion in this study if any of the following criteria apply:\n\n* Individuals diagnosed with COVID-19 virus infection in the past 1-20 days must submit the proved metrics of COVID-19 virus marks positive during the registration;\n* The age of participants is between 10-70 years old;\n* The participants are received or not received conventional medication treatment, and continuing the treatment patients, could be enrolled in this clinical study;\n* This clinical study is not restricted to gender, age, sex, race, and nationality;\n* The participants must have reports of CBC, C3, C4, IgM, IgG, CD4/CD8, and lungs' images ready before the clinical study;\n* The Participants must repeat the evaluation experiment during and at the end of the clinical study.\n\nExclusion Criteria:\n\nA subject will not be eligible for inclusion in this study if any of the following criteria apply:\n\n* Individuals with a prior COVID-19 virus infection that no longer shows up from COVID-19 testing;\n* Children who are younger than 10-year-old, cannot control themselves to take the medical herbs on time;\n* Elders whose age beyond 70-year-old, with severe underline illness;\n* COVID-19 virus-infected patients who do not feel willing to take medical herbs;\n* Patients diagnosed with COVID-19 virus infection cannot consistently finish the treatment courses for a specific reason;\n* Patients diagnosed with COVID-19 virus infection but do not willing to share their information with the public;\n* Current or past participation within a specified timeframe in another clinical trial, as warranted by this intervention's administration;\n* Severe patients, when there have insufficient normal cells, can be adjusted, with pre-list diseases life-threatening.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Wanzhu Hou, CMD, MD(CN)","role":"CONTACT","phone":"1(301)770-4480","email":"info@anmedicine.com"}],"overallOfficials":[{"name":"Wanzhu Hou, CMD,MD(CN)","affiliation":"All Natural Medicine Clinic, LLC","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"All Natural Medicine Clinic, LLC","status":"RECRUITING","city":"Rockville","state":"Maryland","zip":"20852-2235","country":"United States","contacts":[{"name":"Naylla Freitas","role":"CONTACT","phone":"301-770-4480","email":"info@anmedicine.com"}],"geoPoint":{"lat":39.084,"lon":-77.15276}}]},"referencesModule":{"references":[{"type":"BACKGROUND","citation":"Wannzhu Hou Cellular Structure and its Function is the key for heeling Diseases, Certification and Registration number: TXu 1-938-144 July 30, 2014"},{"pmid":"24795718","type":"BACKGROUND","citation":"Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses to viral infections - opportunities for Peptide vaccination. Front Immunol. 2014 Apr 16;5:171. doi: 10.3389/fimmu.2014.00171. eCollection 2014."},{"pmid":"32802404","type":"BACKGROUND","citation":"Zhou LK, Zhou Z, Jiang XM, Zheng Y, Chen X, Fu Z, Xiao G, Zhang CY, Zhang LK, Yi Y. Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients. Cell Discov. 2020 Aug 5;6(1):54. doi: 10.1038/s41421-020-00197-3. eCollection 2020. No abstract available."},{"pmid":"8666349","type":"BACKGROUND","citation":"Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology. 1996 Apr;23(4):909-16. doi: 10.1053/jhep.1996.v23.ajhep0230909. No abstract available."},{"pmid":"23263184","type":"BACKGROUND","citation":"Zhou H, Sun L, Yang XL, Schimmel P. ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. Nature. 2013 Feb 7;494(7435):121-4. doi: 10.1038/nature11774. Epub 2012 Dec 23."},{"pmid":"29669994","type":"BACKGROUND","citation":"Dosch M, Gerber J, Jebbawi F, Beldi G. Mechanisms of ATP Release by Inflammatory Cells. Int J Mol Sci. 2018 Apr 18;19(4):1222. doi: 10.3390/ijms19041222."},{"pmid":"21293466","type":"BACKGROUND","citation":"Chen RJ, Jinn TR, Chen YC, Chung TY, Yang WH, Tzen JT. Active ingredients in Chinese medicines promoting blood circulation as Na+/K+ -ATPase inhibitors. Acta Pharmacol Sin. 2011 Feb;32(2):141-51. doi: 10.1038/aps.2010.197."},{"pmid":"15630483","type":"BACKGROUND","citation":"Samuels N. Herbal remedies and anticoagulant therapy. Thromb Haemost. 2005 Jan;93(1):3-7. doi: 10.1160/TH04-05-0285."},{"pmid":"30776316","type":"BACKGROUND","citation":"Soni S, O'Dea KP, Tan YY, Cho K, Abe E, Romano R, Cui J, Ma D, Sarathchandra P, Wilson MR, Takata M. ATP redirects cytokine trafficking and promotes novel membrane TNF signaling via microvesicles. FASEB J. 2019 May;33(5):6442-6455. doi: 10.1096/fj.201802386R. Epub 2019 Feb 18."},{"type":"RESULT","citation":"Wanzhu Hou, et al. Treating Autoimmune disease with Chinses Medicine, Elsevier, 2011"}],"seeAlsoLinks":[{"label":"We widely treat and research infected and non-infected diseases based on recovering the damaged structure and function of cells.","url":"http://www.anmedicine.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"When we finish the project of the clinical study, we will share the individual participant's data (IPD) (but is not personal private to share) when the results in the publication","infoTypes":["STUDY_PROTOCOL"],"timeFrame":"The clinical study may start on February 1, 2021; the ending of the say maybe is December 31, 2022. The IPD sharing will begin after the publication in six months.","accessCriteria":"Viruses, including COVID-19, are highly likely to mutate. This capacity makes it particularly challenging to kill the virus with drugs. This clinical study designed two groups, both of they used the same drugs, but the treatment group pluses medical herbs, then both groups parallelly receive the treatment, then compare participants symptoms, blood test of immunity, the lungs imagine, and COVID-19 virus index, the difference in both group, analysis the symptoms and the mechanism.","url":"http://www.anmedicine.com"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-03-13"},"conditionBrowseModule":{"meshes":[{"id":"D000086382","term":"COVID-19"}],"ancestors":[{"id":"D007239","term":"Infections"},{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018352","term":"Coronavirus Infections"},{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}],"browseLeaves":[{"id":"M10293","name":"Inflammation","relevance":"LOW"},{"id":"M10283","name":"Infections","relevance":"LOW"},{"id":"M13904","name":"Pneumonia","relevance":"LOW"},{"id":"M16686","name":"Thrombosis","relevance":"LOW"},{"id":"M2561","name":"COVID-19","asFound":"COVID-19","relevance":"HIGH"},{"id":"M2454","name":"Hyperthermia","relevance":"LOW"},{"id":"M6368","name":"Communicable Diseases","relevance":"LOW"},{"id":"M20490","name":"Coronavirus Infections","relevance":"LOW"},{"id":"M6590","name":"Cough","relevance":"LOW"},{"id":"M8464","name":"Fever","relevance":"LOW"},{"id":"M17522","name":"Virus Diseases","relevance":"LOW"},{"id":"M13914","name":"Pneumonia, Viral","relevance":"LOW"},{"id":"M14978","name":"Respiratory Tract Infections","relevance":"LOW"},{"id":"M6555","name":"Coronaviridae Infections","relevance":"LOW"},{"id":"M23685","name":"Nidovirales Infections","relevance":"LOW"},{"id":"M15149","name":"RNA Virus Infections","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC01","name":"Infections"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"BC26","name":"Wounds and Injuries"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M6307","name":"Colchicine","relevance":"LOW"},{"id":"M341627","name":"Remdesivir","relevance":"LOW"},{"id":"M4230","name":"Antibodies, Monoclonal","relevance":"LOW"},{"id":"M10184","name":"Immunoglobulins","relevance":"LOW"},{"id":"M4225","name":"Antibodies","relevance":"LOW"},{"id":"M210428","name":"Bamlanivimab","relevance":"LOW"},{"id":"M21137","name":"Respiratory System Agents","relevance":"LOW"},{"id":"T208","name":"Licorice","relevance":"LOW"},{"id":"T292","name":"Skullcap","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Resp","name":"Respiratory System Agents"},{"abbrev":"HB","name":"Herbal and Botanical"}]}},"hasResults":false}
]